<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002232" GROUP_ID="LIVER" ID="219600013115392124" MERGED_FROM="" MODIFIED="2008-11-14 01:32:29 +0100" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="02" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.9">
<COVER_SHEET MODIFIED="2008-11-14 01:17:10 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2008-11-09 21:41:03 +0100" MODIFIED_BY="[Empty name]">Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients</TITLE>
<CONTACT>
<PERSON ID="4DD5730482E26AA201BA4B54069A499E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Norberto</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Chavez-Tapia</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>khavez@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gastroenterology</DEPARTMENT>
<ORGANISATION>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</ORGANISATION>
<ADDRESS_1>Vasco de Quiroga #5</ADDRESS_1>
<ADDRESS_2/>
<CITY>Mexico City</CITY>
<ZIP>14000</ZIP>
<REGION>Distrito Federal</REGION>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<PHONE_1>(5255) 54870900, ext: 2715</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-14 01:17:10 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="4DD5730482E26AA201BA4B54069A499E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Norberto</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Chavez-Tapia</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>khavez@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gastroenterology</DEPARTMENT>
<ORGANISATION>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</ORGANISATION>
<ADDRESS_1>Vasco de Quiroga #5</ADDRESS_1>
<ADDRESS_2/>
<CITY>Mexico City</CITY>
<ZIP>14000</ZIP>
<REGION>Distrito Federal</REGION>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<PHONE_1>(5255) 54870900, ext: 2715</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12341" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Karla</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Soares-Weiser</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>karla@enhance-reviews.com</EMAIL_1>
<EMAIL_2>ksoares@netvision.net.il</EMAIL_2>
<URL>www.enhance-reviews.com</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Enhance Reviews</ORGANISATION>
<ADDRESS_1>PO Box 137</ADDRESS_1>
<ADDRESS_2/>
<CITY>Kfar-Saba</CITY>
<ZIP>44101</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1>+972 9 767 3223</PHONE_1>
<PHONE_2/>
<FAX_1>+972 9 767 0103</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13982" ROLE="AUTHOR">
<PREFIX>Professor</PREFIX>
<FIRST_NAME>Mayer</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Brezis</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>brezis@vms.huji.ac.il</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Center for Clinical Quality &amp; Safety</DEPARTMENT>
<ORGANISATION>Hadassah Hebrew University Hospital</ORGANISATION>
<ADDRESS_1>Ein Kerem Campus Box 53</ADDRESS_1>
<ADDRESS_2>POB 12000</ADDRESS_2>
<CITY>Jerusalem</CITY>
<ZIP>91120</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1>+972 2 677 7110</PHONE_1>
<PHONE_2>+972 2 50 787 4596</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12295" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Leonard</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Leibovici</LAST_NAME>
<SUFFIX/>
<POSITION>Head</POSITION>
<EMAIL_1>leibovic@post.tau.ac.il</EMAIL_1>
<EMAIL_2>leibovici@clalit.org.il</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine E</DEPARTMENT>
<ORGANISATION>Beilinson Campus, Rabin Medical Center</ORGANISATION>
<ADDRESS_1>39 Jabotinsky Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Petah-Tiqva</CITY>
<ZIP>49100</ZIP>
<REGION/>
<COUNTRY CODE="IL">Israel</COUNTRY>
<PHONE_1>+972 3 9376501</PHONE_1>
<PHONE_2>+972 3 9376506</PHONE_2>
<FAX_1>+972 3 9376505</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-24 15:47:10 +0200" MODIFIED_BY="dimitrinka nikolova">
<UP_TO_DATE>
<DATE DAY="30" MONTH="5" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="7" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="8" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-10 15:41:16 +0100" MODIFIED_BY="dimitrinka nikolova">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-11-10 15:41:16 +0100" MODIFIED_BY="dimitrinka nikolova">
<DATE DAY="24" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>The conclusions remain as in the previous published review version. New lead author.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-27 17:11:32 +0100" MODIFIED_BY="dimitrinka nikolova">
<DATE DAY="24" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="17" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-27 17:10:46 +0100" MODIFIED_BY="dimitrinka nikolova"/>
<SOURCES_OF_SUPPORT MODIFIED="2008-07-24 20:05:05 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-07-24 20:05:05 +0200" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Tel Aviv University</NAME>
<COUNTRY CODE="IL">Israel</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Hadassah University Hospital - Mount Scopus</NAME>
<COUNTRY CODE="IL">Israel</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Rabin Medical Center - Beilison Campus</NAME>
<COUNTRY CODE="IL">Israel</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-07-24 20:05:05 +0200" MODIFIED_BY="[Empty name]">
<NAME>Fellowship in Translational Hepatology by the CSF</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Danish Medical Research Council Grant on Getting Research into Practice (GRIP)</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-14 01:25:03 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-13 20:28:23 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-09 21:41:33 +0100" MODIFIED_BY="[Empty name]">Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-13 20:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>Cirrhosis is a severe end-stage liver disease marked by irreversible scarring of liver tissue. Ascites (the accumulation of fluid in the abdomen), is one of the many complications associated with cirrhosis. Ascites is associated with poor quality of life, increased risk of infection, and renal failure. The presence of ascites is a sign of poor prognosis. Spontaneous bacterial peritonitis (inflammation and infection of the membrane that is lining the abdominal cavity) is a complication of cirrhotic ascites that occurs in the absence of any intra-abdominal, surgically treatable source of infection. Antibiotic therapy is indicated and should be initiated as soon as possible to avoid severe complications that may lead to death. This review aimed to evaluate the beneficial and harmful effects of different types and modes of antibiotic therapy in the treatment of spontaneous bacterial peritonitis in cirrhotic patients. Thirteen trials were included; each one of them compared different antibiotics in their experimental and control groups. No meta-analyses could be performed, though data on the main outcomes were collected and analysed separately for each included trial. Based on the identified evidence, we cannot suggest the most appropriate management to treat spontaneous bacterial peritonitis in regard to the type, dosage, duration, or administration route of the antibiotic therapy. The clinical trials found dealt with different types of antibiotics, and, therefore, could not be combined. This review found no evidence that the effect or safety of one antibiotic is more beneficial than another. Further randomised clinical trials with an adequate design, including a large number of participants and sufficient duration should be carefully planned to provide a more precise estimate of the beneficial and harmful effects of antibiotic treatment for spontaneous bacterial peritonitis.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-13 20:27:32 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-11-13 20:24:25 +0100" MODIFIED_BY="[Empty name]">
<P>Spontaneous bacterial peritonitis is a complication of cirrhotic ascites that occurs in the absence of any intra-abdominal, surgically treatable source of infection. Antibiotic therapy is indicated and should be initiated as soon as possible to avoid severe complications that may lead to death. It has been proposed that empirical treatment should cover gram-negative enteric bacteria and gram-positive cocci, responsible for up to 90% of spontaneous bacterial peritonitis cases.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-11-13 20:25:07 +0100" MODIFIED_BY="[Empty name]">
<P>This review aims to evaluate the beneficial and harmful effects of different types and modes of antibiotic therapy in the treatment of spontaneous bacterial peritonitis in cirrhotic patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-07-24 19:57:34 +0200" MODIFIED_BY="[Empty name]">
<P>We performed electronic searches in <I>The Cochrane Hepato-Biliary Group Controlled Trials Register </I>(July 2008), the <I>Cochrane Central Register of Controlled Trials</I> (<I>CENTRAL</I>) in <I>The Cochrane Library</I> (Issue 3, 2008), <I>MEDLINE </I>(1950 to July 2008), <I>EMBASE</I> (1980 to July 2008), and <I>Science Citation Index EXPANDED </I>(1945 to July 2008). In addition, we handsearched the references of all identified studies and contacted the first author of each included trial.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-11-10 15:42:22 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised studies comparing different types of antibiotics for spontaneous bacterial peritonitis in cirrhotic patients.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-11-10 16:12:37 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Data were independently extracted from the trials by at least two authors. Peto odds ratios or average differences, with their 95% confidence intervals, were estimated.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-10 17:47:21 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>This systematic review attempted to summarise evidence from randomised clinical trials on the treatment of spontaneous bacterial peritonitis. Thirteen studies were included; each one of them compared different antibiotics in their experimental and control groups. No meta-analyses could be performed, though data on the main outcomes were collected and analysed separately for each included trial. Currently, the evidence showing that lower dosage or short-term treatment with third generation cephalosporins is as effective as higher dosage or long-term treatment is weak. Oral quinolones could be considered an option for those with less severe manifestations of the disease.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-13 20:27:32 +0100" MODIFIED_BY="[Empty name]">
<P>This review provides no clear evidence for the treatment of cirrhotic patients with spontaneous bacterial peritonitis. In practice, third generation cephalosporins have already been established as the standard treatment of spontaneous bacterial peritonitis, and it is clear, that empirical antibiotic therapy should be provided in any case. However, until large, well-conducted trials provide more information, practice will remain based on impression, not evidence.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-14 01:25:03 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-14 01:19:33 +0100" MODIFIED_BY="[Empty name]">
<P>Ascites is the most common major complication of cirrhosis; it is associated with poor quality of life, increased risk of infection, and renal failure. Ascites is also a poor prognostic sign. Characteristically, it develops during late stages of the disease and indicates disturbances in the water and sodium retention, arterial dysfunction, and portal hypertension (<LINK REF="REF-Leiva-2007" TYPE="REFERENCE">Leiva 2007</LINK>).</P>
<P>Spontaneous bacterial peritonitis is a frequent complication of ascites in patients with cirrhosis. It is secondary to impaired humoral and cellular immune responses and to the ascitic fluid acting as culture medium for several bacterial agents (<LINK REF="REF-Chavez_x002d_Tapia-2007" TYPE="REFERENCE">Chavez-Tapia 2007</LINK>).</P>
<P>The diagnosis of spontaneous bacterial peritonitis is based on the polymorphonuclear (PMN) cell count in ascitic fluid. A PMN count of more than 250/mm<SUP>3</SUP> is highly suspicious of spontaneous bacterial peritonitis and constitutes an indication to initiate empiric antibiotic treatment (in patients with haemorrhagic ascites (ascites red blood cells count &gt; 10 000/mm<SUP>3</SUP>), a subtraction of one PMN per 250 red blood cells should be made to adjust for the presence of blood in ascites). A diagnosis of spontaneous bacterial peritonitis established only on the basis of symptoms and signs is less reliable. Bacterascites refers to the colonization of ascitic fluid by bacteria in the absence of an inflammatory reaction in the peritoneal fluid. Therefore, the diagnosis of bacterascites is currently made when 1) there is a positive ascitic fluid culture in the setting of an ascitic fluid PMN count &lt;250/mm<SUP>3</SUP> or 2) there is secondary peritonitis (<LINK REF="REF-Rimola-2000" TYPE="REFERENCE">Rimola 2000</LINK>).</P>
<P>Several risk factors have been associated with spontaneous bacterial peritonitis. The most important are a) low serum sodium level, b) low ascitic fluid total protein (<LINK REF="REF-Kaymakoglu-1997" TYPE="REFERENCE">Kaymakoglu 1997</LINK>), and the c) Model for End-Stage Liver Disease score (<LINK REF="REF-Obstein-2007" TYPE="REFERENCE">Obstein 2007</LINK>).</P>
<P>The incidence varies widely and depends on the clinical setting. For example in cirrhotic outpatients undergoing large-volume paracentesis, the prevalence varies from 0% to 0.5% (<LINK REF="REF-Castellote-2008" TYPE="REFERENCE">Castellote 2008</LINK>). On other hand in patients admitted to a liver units, the prevalence reaches 16.3% (<LINK REF="REF-Fasolato-2007" TYPE="REFERENCE">Fasolato 2007</LINK>), with a mortality rate of 10% to 32.6% (<LINK REF="REF-Thuluvath-2001" TYPE="REFERENCE">Thuluvath 2001</LINK>; <LINK REF="REF-Thanapoulou-2002" TYPE="REFERENCE">Thanapoulou 2002</LINK>).</P>
<P>Antibiotic treatment should be started as soon as the diagnosis is made (based on the PMN count in the ascites). The most commonly observed agents are <I>Escherichia coli</I>, Klebsiella, <I>Staphylococcus aureus</I>, <I>Enterococcus faecalis</I>, and <I>Streptococcus pneumonia </I>(<LINK REF="REF-Franc_x00e9_s-2008" TYPE="REFERENCE">Francés 2008</LINK>).</P>
<P>The recommended and most commonly used antibiotics are third-generation cephalosporins, the most commonly used agent of this<SUP> </SUP>class of antibiotics is cefotaxime, although other agents like<SUP> </SUP>ceftriaxone and ceftazidime have similar efficacy. Patients on antibiotic prophylaxis have a higher chance of being infected by a Gram-positive micro-organism. An important recent finding is that intravenous administration of albumin to patients with spontaneous bacterial peritonitis reduces the risk of complications, such as hepatorenal syndrome, and may significantly improve survival (<LINK REF="REF-Kuiper-2007" TYPE="REFERENCE">Kuiper 2007</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-11-12 12:02:17 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>To evaluate the beneficial and harmful effects of different types of antibiotic therapy in the treatment of spontaneous bacterial peritonitis in cirrhotic patients.</LI>
<LI>To estimate the mortality and frequency of spontaneous bacterial peritonitis recurrence.</LI>
<LI>To assess the frequency of adverse effects associated with different types of antibiotic therapy.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-14 01:20:32 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-14 00:55:07 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-11-13 20:45:09 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify any randomised clinical trial comparing different types of antibiotic therapy, regardless of dose, route of administration or schedule, for the treatment of spontaneous bacterial peritonitis in cirrhotic patients. The studies were included regardless of language and publication status.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-12 12:08:29 +0100" MODIFIED_BY="[Empty name]">
<P>Cirrhotic patients, adults, irrespective of sex or nationality, who developed an infection of the ascitic fluid in the absence of another local source of infection, and received antibiotic therapy.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-14 00:55:07 +0100" MODIFIED_BY="[Empty name]">
<P>We considered the interventions given below no matter whether they had been used as a single intervention or in combination. For the control group, we considered placebo or no intervention, or any of the following antibiotics:</P>
<P>Intravenous antibiotic therapy</P>
<UL>
<LI>Aminoglycoside (gentamicin, tobramycin);</LI>
<LI>Beta-lactam (ampicillin, cephalotin);</LI>
<LI>Third generation cephalosporin (cefotaxime, ceftriaxone, cefonicid);</LI>
<LI>Amoxycillin + clavulanic acid;</LI>
<LI>Aztreonam.</LI>
</UL>
<P>Oral antibiotic therapy</P>
<UL>
<LI>Quinolones (pefloxacin, ofloxacin);</LI>
<LI>Amoxycillin;</LI>
<LI>Trimethoprim/sulphamethoxazole.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-12 23:53:34 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-11-10 23:02:48 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Death.</LI>
<LI>Cure.</LI>
<LI>Recurrence of spontaneous bacterial peritonitis.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-12 23:53:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Numbers of days of hospitalisation.</LI>
<LI>Adverse events:</LI>
</UL>
<P>- Any serious adverse event that is fatal, life-threatening, requiring inpatient hospitalisation or prolongation of existing hospitalisation; significant disability or incapacity or any important medical event that may not be immediately life-threatening or results in death or hospitalisation, but may jeopardise the patient or may require intervention to prevent one of the above outcomes.</P>
<P>- Any adverse event that requires discontinuation of medication (<LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-13 20:49:37 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-13 20:49:37 +0100" MODIFIED_BY="[Empty name]">
<P>Relevant randomised trials were identified by searching the <I>Cochrane Hepato-Biliary Group Controlled Trials Register </I>(<LINK REF="REF-Gluud-2008" TYPE="REFERENCE">Gluud 2008</LINK>), the <I>Cochrane Central Register of Controlled Trials </I>(<I>CENTRAL</I>) in <I>The Cochrane Library </I>(Issue 3, 2008), <I>MEDLINE</I> (1950 to July 2008), <I>EMBASE </I>(1980 to September 2008)<I>, </I>and <I>Science Citation Index EXPANDED </I>(1945 to July 2008) (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>). The search strategies used are given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> with the time span of the searches.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-07-23 10:29:03 +0200" MODIFIED_BY="[Empty name]">
<P>The references of all identified studies were inspected for more studies. Additionally, the first or corresponding author of each included study, and the researchers active in the field, were contacted for information regarding unpublished trials or complementary information on their own trial.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-14 01:20:32 +0100" MODIFIED_BY="[Empty name]">
<P>We followed the instructions given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2008" TYPE="REFERENCE">Gluud 2008</LINK>).</P>
<STUDY_SELECTION MODIFIED="2008-11-12 21:33:07 +0100" MODIFIED_BY="[Empty name]">
<P>Three authors (KSW, MB, and NC) independently inspected the abstract of each reference identified by the search and applied the inclusion criteria. For possible relevant articles, or in cases of disagreement between the two authors, the full article was obtained and inspected independently by the three authors (KSW, MB, and NC). Where resolving disagreement by discussion was not possible, the article was added to those '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>' and the authors of the study contacted for clarification. In an event of no reply from the authors within six months, an internal ombudsman was used to solve the disagreements. Quasi-randomised studies were included only after agreement of at least two reviewers.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-14 01:20:32 +0100" MODIFIED_BY="[Empty name]">
<P>Three authors (KSW, MB, and NC) independently extracted the data of included trials. In case of disagreement between the three authors, a fourth author (LL) extracted the data. The data extraction was discussed, decisions documented, and, where necessary, the authors of the studies were contacted for clarification. Justification for excluding studies from the review was documented.</P>
<P>Trials were identified by the name of the first author and year in which the trial was first published, and ordered chronologically. The following data were extracted, checked, and recorded:</P>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of trials</HEADING>
<OL>
<LI>Publication status.</LI>
<LI>Case definitions used (clinical, serological, bacteriological).</LI>
<LI>Sponsor of trial (specified, known or unknown).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of participants</HEADING>
<OL>
<LI>Number of participants in each group.</LI>
<LI>Age, gender, country.</LI>
<LI>Severity of liver disease and cirrhosis according to the aetiology of liver disease, regardless of the criteria used.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of interventions</HEADING>
<OL>
<LI>Type of antibiotic, dose, route of administration, schedule, length of follow-up (in months).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of outcome measures</HEADING>
<OL>
<LI>Number of deaths in the treatment and control group.</LI>
<LI>Number of cured or recurrences in each group.</LI>
<LI>Number of days of hospitalisation.</LI>
<LI>Fatal or life-threatening adverse events.</LI>
<LI>Any other adverse or medical event related to the treatment.</LI>
<LI>Lost of follow-up (dropouts) after randomisation.</LI>
</OL>
<P>Two authors (KSW, NC) entered data in Review Manager Version 5.0 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). Continuous outcomes were expressed as mean differences with 95% confidence intervals while dichotomous outcomes were expressed as relative risks with a 95% confidence interval (CI). For each outcome, we extracted the number of participants assigned to each group, and whenever possible we extracted data to allow for an intention-to-treat analysis. If the number randomised and the numbers analysed were inconsistent, we reported this as the percentage lost to follow-up. For binary outcomes, we recorded the number of participants experiencing the event in each group. For continuous outcomes, we extracted the arithmetic means and standard deviations for each group. Any disagreement was resolved by discussion with reference to the trial report and resolution by a co-author (MB). For outcomes for which data were not reported or were reported in a different format, we contacted the authors for clarification.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-11-13 15:13:35 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (NC, KSW) assessed bias risk of the trials independently, without masking of the trial names. We followed the instructions given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and the <I>Cochrane Hepato-Biliary Group Module</I> (<LINK REF="REF-Gluud-2008" TYPE="REFERENCE">Gluud 2008</LINK>). Due to the risk of biased overestimation of intervention effects in randomised trials with inadequate methodological quality (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>), we assessed the influence of methodological quality of the trials on the results by evaluating the methodological components described below. If information was not available in the published trial, we contacted the authors in order to assess the trials correctly.</P>
<P>
<I>
<B>Generation of the allocation sequence</B>
</I>
<BR/>
</P>
<UL>
<LI>Adequate, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice were also considered as adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described.</LI>
<LI>Inadequate, if a system involving dates, names, or admittance numbers were used for the allocation of patients.</LI>
</UL>
<P>
<I>
<B>Allocation concealment </B>
</I>
<B>
<BR/>
</B>
</P>
<UL>
<LI>Adequate, if the allocation of patients involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described.</LI>
<LI>Inadequate, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.</LI>
</UL>
<P>
<I>
<B>Blinding</B>
</I>
<B>
<BR/>
</B>
</P>
<UL>
<LI>Adequate, if the trial was described as double blind and the method of blinding involved identical placebo or active drugs.</LI>
<LI>Unclear, if the trial was described as double blind, but the method of blinding was not described.</LI>
<LI>Not performed, if the trial was not double blind.</LI>
</UL>
<P>
<I>
<B>Incomplete data outcomes</B>
</I>
</P>
<UL>
<LI>Adequate, if there were no post-randomisation drop-outs or withdrawals.</LI>
<LI>Unclear, if it is not clear whether there are any drop-outs or withdrawals or if the reasons for these drop-outs are not clear.</LI>
<LI>Inadequate, if the reasons for missing data are likely to be related to true outcomes.</LI>
</UL>
<P>
<I>
<B>Selective outcome reporting</B>
</I>
</P>
<UL>
<LI>Low risk of bias (considering that most of the included trials were made before of the obligatory registration on randomised controlled trials databases, and the pre-specified outcomes are not available. The following outcomes were considered fundamental as outcome to avoid selective reporting a) mortality, b) response rate, and c) adverse events).</LI>
<LI>Uncertain risk of bias (there is insufficient information to assess whether the magnitude and direction of the observed effect is related to selective outcome reporting).</LI>
<LI>High risk of bias (not all of the trial's pre-specified primary outcomes have been reported or similar).</LI>
</UL>
<P>
<I>
<B>Other sources of bias</B>
</I>
<B> </B>
</P>
<UL>
<LI>Low risk of bias (the trial appears to be free of other sources of bias, considering a) baseline imbalance, b) source of funding, c) early stopping, and d) interim analysis).</LI>
<LI>Uncertain risk of bias (there is insufficient information to assess whether other sources of bias are present).</LI>
<LI>High risk of bias (it is likely that potential sources of bias).</LI>
</UL>
<P>
<I>
<B>Follow-up</B>
</I>
<BR/>
</P>
<UL>
<LI>Adequate, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals.</LI>
<LI>Unclear, if the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.</LI>
<LI>Inadequate, if the number or reasons for dropouts and withdrawals were not described.</LI>
</UL>
<P>Furthermore, we registered whether or not the randomised clinical trials had used 'intention-to-treat' analysis (<LINK REF="REF-Gluud-2001" TYPE="REFERENCE">Gluud 2001</LINK>) and sample size calculation.</P>
<P>Any disagreement was resolved by discussion and settled by a third author (MB). We contacted the trial author for clarification as necessary.</P>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-11-13 21:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to check the heterogeneity among trials by visual inspection of the forest plots and by using the chi-squared and I<SUP>2</SUP> tests for heterogeneity (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). Statistical heterogeneity was defined as P-value &#8804; 0.10 (chi-squared) or I<SUP>2 </SUP>&gt; 25%. When heterogeneity existed, we would have explored the potential sources of heterogeneity according to:</P>
<UL>
<LI>Intervention (type of antibiotic, route of administration, and schedule).</LI>
<LI>Participants (stage of cirrhosis, history of antibiotic prophylaxis, and presence of bleeding).</LI>
<LI>Trial quality (risk of bias scores).</LI>
</UL>
<P>Subgroup analyses were planned in order to assess the impact of these possible sources of heterogeneity in the main results.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-11-13 22:20:45 +0100" MODIFIED_BY="[Empty name]">
<P>We used a funnel plot to explore bias. It was not possible to perform linear regression approach described by Egger et al to determine the funnel plot asymmetry (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-11-10 17:34:13 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>For the statistical analyses, we used RevMan Analyses (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). Dichotomous data were analysed by calculating the Peto odds ratios for each trial with the uncertainty in each result being expressed using 95% confidence intervals (fixed-effect model).</P>
<P>Where possible, comparisons were made between the mean duration of symptoms in the two groups. These continuous data were analysed by using the mean and standard deviation of each trial and calculating the effect size (average mean difference) and the 95% confidence interval (fixed-effect model).</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-11-13 20:58:08 +0100" MODIFIED_BY="[Empty name]">
<P>We analysed data by both the fixed-effect model analysis and random-effects model analysis, but only reported the former in the text if the outcome of both analyses were the same. Outcomes were analysed as reported in the trial, that is, either per protocol or as intention-to-treat analysis. In order to examine the influence of drop outs, we performed both worst-case (assigning bad outcomes to all of the missing experimental arm patients and good outcomes to all of the missing control arm patients) and best-case (assigning good outcomes to all of the missing experimental arm patients and bad outcomes to all of the missing control arm patients) analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-14 01:25:03 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-13 21:01:41 +0100" MODIFIED_BY="[Empty name]">
<P>Thirteen studies were included in the review (<LINK REF="STD-Rimola-1984" TYPE="STUDY">Rimola 1984</LINK>; <LINK REF="STD-Felisart-1985" TYPE="STUDY">Felisart 1985</LINK>; <LINK REF="STD-Runyon-1991" TYPE="STUDY">Runyon 1991</LINK>; <LINK REF="STD-Gomez_x002d_Jimenez-1993" TYPE="STUDY">Gomez-Jimenez 1993</LINK>; <LINK REF="STD-Rimola-1995" TYPE="STUDY">Rimola 1995</LINK>; <LINK REF="STD-Figueiredo-1996" TYPE="STUDY">Figueiredo 1996</LINK>; <LINK REF="STD-Navasa-1996" TYPE="STUDY">Navasa 1996</LINK>; <LINK REF="STD-Terg-1997" TYPE="STUDY">Terg 1997</LINK>; <LINK REF="STD-Ricart-2000" TYPE="STUDY">Ricart 2000</LINK>; <LINK REF="STD-Tuncer-2003" TYPE="STUDY">Tuncer 2003</LINK>; <LINK REF="STD-Grange-2004" TYPE="STUDY">Grange 2004</LINK>; <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Angeli--2006" TYPE="STUDY">Angeli 2006</LINK>). Six of them were conducted in Spain, one in Brazil, USA, Italy, Taiwan, France, Turkey and Argentina respectively (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies'</LINK> for details).</P>
<P>Thirteen studies were excluded from this review because of lack of randomisation procedure (<LINK REF="STD-Fong-1989" TYPE="STUDY">Fong 1989</LINK>; <LINK REF="STD-Mercader-1989" TYPE="STUDY">Mercader 1989</LINK>; <LINK REF="STD-Silvain-1989" TYPE="STUDY">Silvain 1989</LINK>; <LINK REF="STD-Llovet--1993" TYPE="STUDY">Llovet 1993</LINK>; <LINK REF="STD-Fernandez-2002" TYPE="STUDY">Fernandez 2002</LINK>; <LINK REF="STD-Taskiran--2004" TYPE="STUDY">Taskiran 2004</LINK>) or quasi-randomised design (<LINK REF="STD-Ariza-1991" TYPE="STUDY">Ariza 1991</LINK>; <LINK REF="STD-Rastegar-1998" TYPE="STUDY">Rastegar 1998</LINK>), or less than 10% of the patients had spontaneous bacterial peritonitis (<LINK REF="STD-Sifuentes-1989" TYPE="STUDY">Sifuentes 1989</LINK>; <LINK REF="STD-McCormick-1997" TYPE="STUDY">McCormick 1997</LINK>), or because there was no antibiotic comparison (<LINK REF="STD-Franca-2002" TYPE="STUDY">Franca 2002</LINK>), or because the trial was published only as an abstract and contained no relevant information about the trial design (<LINK REF="STD-Pariente-1988" TYPE="STUDY">Pariente 1988</LINK>). We contacted the authors of the latter in order to obtain further information, but they did not reply.</P>
<P>Most patients in the included trials had diagnostic of spontaneous bacterial peritonitis confirmed by ascitic fluid PMN more than 250/mm<SUP>3</SUP> and positive ascitic culture. <LINK REF="STD-Grange-2004" TYPE="STUDY">Grange 2004</LINK> did not report confirmation of spontaneous bacterial peritonitis diagnosis. Seven trials had the stage of cirrhosis determined by the Child-Pugh score (<LINK REF="STD-Runyon-1991" TYPE="STUDY">Runyon 1991</LINK>; <LINK REF="STD-Gomez_x002d_Jimenez-1993" TYPE="STUDY">Gomez-Jimenez 1993</LINK>; <LINK REF="STD-Rimola-1995" TYPE="STUDY">Rimola 1995</LINK>; <LINK REF="STD-Terg-1997" TYPE="STUDY">Terg 1997</LINK>; <LINK REF="STD-Ricart-2000" TYPE="STUDY">Ricart 2000</LINK>; <LINK REF="STD-Tuncer-2003" TYPE="STUDY">Tuncer 2003</LINK>; <LINK REF="STD-Angeli--2006" TYPE="STUDY">Angeli 2006</LINK>). In another two trials (<LINK REF="STD-Felisart-1985" TYPE="STUDY">Felisart 1985</LINK>; <LINK REF="STD-Ricart-2000" TYPE="STUDY">Ricart 2000</LINK>), 20% and 50% of the patients, respectively, were diagnosed with bacteraemia, urinary tract infection, or pneumonia when included in the trial.</P>
<P>Neither included trial compared similar experimental and control treatments; therefore, no statistical combination could be performed. <LINK REF="STD-Angeli--2006" TYPE="STUDY">Angeli 2006</LINK> compared IV ciprofloxacin versus IV ceftazidime; <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK> compared IV cefotaxim versus IV amikacin; <LINK REF="STD-Felisart-1985" TYPE="STUDY">Felisart 1985</LINK> compared IV cefotaxime versus IV ampicillin-tobramycin; <LINK REF="STD-Figueiredo-1996" TYPE="STUDY">Figueiredo 1996</LINK> compared IV versus oral cephalosporins; <LINK REF="STD-Gomez_x002d_Jimenez-1993" TYPE="STUDY">Gomez-Jimenez 1993</LINK> compared two types of IV cephalosporins; <LINK REF="STD-Grange-2004" TYPE="STUDY">Grange 2004</LINK> compared IV/PO moxifloxacin versus IV/PO amoxicillin-clavulanic acid; <LINK REF="STD-Navasa-1996" TYPE="STUDY">Navasa 1996</LINK> compared IV cefotaxime versus oral ofloxacin; <LINK REF="STD-Ricart-2000" TYPE="STUDY">Ricart 2000</LINK> compared IV + oral amoxicillin-clavulanic acid versus IV cefotaxime; <LINK REF="STD-Rimola-1984" TYPE="STUDY">Rimola 1984</LINK> compared ampicillin-tobramycin versus ampicillin-tobramycin-neomycin-colistin-nistatin; <LINK REF="STD-Rimola-1995" TYPE="STUDY">Rimola 1995</LINK> compared low versus high dosages of cefotaxime; <LINK REF="STD-Runyon-1991" TYPE="STUDY">Runyon 1991</LINK> compared short, 5 days-term treatment versus long, 10 days-term treatment with cefotaxime; <LINK REF="STD-Terg-1997" TYPE="STUDY">Terg 1997</LINK> compared IV ciprofloxacin versus IV + oral ciprofloxacin and <LINK REF="STD-Tuncer-2003" TYPE="STUDY">Tuncer 2003</LINK> compared oral ciprofloxacin versus IV cefotaxime with IV ceftriaxone.</P>
<P>We also contacted all the authors of the included trials in order to obtain missing details in the reports of their trials.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-14 01:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>The most important bias observed in the trials was lack of a proper blinding. This is intrinsic bias due to the fact that dosages and timing are different among the drugs assessed. However, an important bias element is the incomplete outcome (being the most common, the exclusion of death events during the first 24 to 48 hs), and only three trials describe properly the allocation concealment (<LINK REF="STD-Runyon-1991" TYPE="STUDY">Runyon 1991</LINK>; <LINK REF="STD-Navasa-1996" TYPE="STUDY">Navasa 1996</LINK>; <LINK REF="STD-Angeli--2006" TYPE="STUDY">Angeli 2006</LINK>). The source of outcome bias was limited since the vast majority of the trials described their outcomes completely (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-13 21:10:19 +0100" MODIFIED_BY="[Empty name]">
<P>All the included trials had data on the main outcomes, death and spontaneous bacterial peritonitis resolution.</P>
<P>No meta-analyses could be performed, as each trial compared different antibiotics in their experimental and control group. In an attempt to provide evidence-based information regarding the treatment of spontaneous bacterial peritonitis in patients with cirrhosis, data for each included trial were analysed. We provide the results bellow:</P>
<P>
<LINK REF="STD-Rimola-1984" TYPE="STUDY">Rimola 1984</LINK> compared ampicillin-tobramycin-neomycin-nystatin-colistin with ampicillin-tobramycin in 37 patients. No significant difference was observed in mortality (Peto OR 2.08, 95% CI 0.58 to 7.46) or no resolution of spontaneous bacterial peritonitis (Peto OR 2.53, 95% CI 0.57 to 11.13).</P>
<P>In <LINK REF="STD-Felisart-1985" TYPE="STUDY">Felisart 1985</LINK>, cefotaxime was compared with a combination of ampicillin and tobramycin in 73 patients. In this trial there was no significant difference in the number of people who died (Peto OR 1.57, 95% CI 0.59 to 4.14) or with fatal adverse events (Peto OR 0.13, 95% CI 0.00 to 6.64). There was, however, a significant difference in favour of cefotaxime in the resolution of spontaneous bacterial peritonitis (Peto OR 0.34, 95% CI 0.13 to 0.87).</P>
<P>
<LINK REF="STD-Runyon-1991" TYPE="STUDY">Runyon 1991</LINK> tried to evaluate whether short and long-term treatment would have had the same effect in the resolution of spontaneous bacterial peritonitis and reduce mortality in 90 patients. The results reported no significant difference neither in mortality (Peto OR 0.66, 95% CI 0.28 to 1.53) nor in no resolution of spontaneous bacterial peritonitis (Peto OR 1.15, 95% CI 0.49 to 2.71) for those receiving cefotaxime for five or ten days. In addition, relapse and/or reinfection were similar in the two groups (Peto OR 0.90, 95% CI 0.26 to 3.16).</P>
<P>
<LINK REF="STD-Gomez_x002d_Jimenez-1993" TYPE="STUDY">Gomez-Jimenez 1993</LINK> also compared two third generation cephalosporins administered intravenously (cefonicid versus ceftriaxone) in 60 patients. No significant difference was found between the two groups for any of the outcomes. The results for the primary outcomes were death (Peto OR 1.34, 95% CI 0.46 to 3.89) and no resolution of spontaneous bacterial peritonitis (Peto OR 7.93, 95% CI 0.79 to 79.26).</P>
<P>
<LINK REF="STD-Rimola-1995" TYPE="STUDY">Rimola 1995</LINK> appraised whether lower dosages of cefotaxime had the same effectiveness and less adverse events than higher dosages in 143 cirrhotic patients with spontaneous bacterial peritonitis. Again, no significant difference was found for any of the outcomes provided. The results for the primary outcomes were death (Peto OR 0.59, 95% CI 0.28 to 1.25) and no resolution of spontaneous bacterial peritonitis (Peto OR 0.98, 95% CI 0.44 to 2.19).</P>
<P>In <LINK REF="STD-Figueiredo-1996" TYPE="STUDY">Figueiredo 1996</LINK>, two third generation cephalosporins (oral cefixime versus IV ceftriaxone) were compared in 38 patients. No significant difference was found for death (Peto OR 1.24, 95% CI 0.25 to 6.28) or no resolution of spontaneous bacterial peritonitis (Peto OR 1.81, 95% CI 0.18 to 18.64). Personal communication with the first author provided information for all outcomes. No significant difference could be found between the experimental (cefixime) or control (ceftriaxone) groups.</P>
<P>
<LINK REF="STD-Navasa-1996" TYPE="STUDY">Navasa 1996</LINK> compared oral ofloxacin with IV cefotaxime in 123 patients with uncomplicated spontaneous bacterial peritonitis (patients with hepatic encephalopathy, renal failure, vomiting, ileus, shock or gastrointestinal haemorrhage were excluded from the trial). There was no difference found in the number of deaths between the two groups (Peto OR 1.01, 95% CI 0.41 to 2.49), no resolution of spontaneous bacterial peritonitis (Peto OR 1.03, 95% CI 0.39 to 2.73), or in the presence of adverse events (Peto OR 0.92, 95% CI 0.13 to 6.70).</P>
<P>
<LINK REF="STD-Terg-1997" TYPE="STUDY">Terg 1997</LINK> compared oral + IV with IV ciprofloxacin in 80 cirrhotic patients with spontaneous bacterial peritonitis. No difference was found between the two groups for the outcomes of death (Peto OR 1.00, 95% CI 0.38 to 2.65) and no resolution of spontaneous bacterial peritonitis (Peto OR 1.16, 95% CI 0.40 to 3.36).</P>
<P>
<LINK REF="STD-Ricart-2000" TYPE="STUDY">Ricart 2000</LINK> compared amoxicillin-clavulanic acid with cefotaxime in 96 cirrhotic patients with bacterial infections, 50% of them had spontaneous bacterial peritonitis (and only these patients were analysed in this review). No significant difference was found between the two groups for any of the outcomes. Following are the results for the primary outcomes for patients with spontaneous bacterial peritonitis: death (Peto OR 0.56, 95% CI 0.12 to 2.50), and no resolution of spontaneous bacterial peritonitis (Peto OR 0.72, 95% CI 0.15 to 3.52).</P>
<P>
<LINK REF="STD-Tuncer-2003" TYPE="STUDY">Tuncer 2003</LINK> compared ciprofloxacin with cefotaxime or ceftriaxone in 53 patients. No significant differences in death between ciprofloxacin and cefotaxime (Peto OR 1.15, 95% CI 0.20 to 6.55), ciprofloxacin and ceftriaxone (Peto OR 0.66, 95% CI 0.14 to 3.14) or ceftriaxone and cefotaxime (Pero OR 3, 95% CI 0.38 to 23.47) were observed. No resolution of spontaneous bacterial peritonitis was not significantly different in all comparisons as well (ciprofloxacin versus cefotaxime: Peto OR 0.87, 95% CI 0.19 to 3.92; ciprofloxacin versus ceftriaxone: Peto OR 0.94, 95% CI 0.21 to 4.19; ceftriaxone versus cefotaxime: Peto OR 0.53, 95% CI 0.11 to 2.53).</P>
<P>In <LINK REF="STD-Grange-2004" TYPE="STUDY">Grange 2004</LINK>, moxifloxacin and amoxicillin-clavulanic acid were compared in 35 patients. No significant difference in resolution of spontaneous bacterial peritonitis was observed (Peto OR 6.99, 95% CI 0.14 to 352.83).</P>
<P>In <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>, amikacin was compared to cefotaxime in 37 patients. No significant difference was observed in death (Peto OR 1.43, 95% CI 0.32 to 6.28), and the difference in resolution of spontaneous bacterial peritonitis did not reach statistical significance (Peto OR 2.29, 95% CI 0.57 to 9.23).</P>
<P>Finally, <LINK REF="STD-Angeli--2006" TYPE="STUDY">Angeli 2006</LINK>, intravenous ciprofloxacin was compared to ceftazidime in different doses (according to the creatinine level) in 116 patients. No significant differences were found for death (Peto OR 0.55, 95% CI 0.21 to 1.43) or no resolution of spontaneous bacterial peritonitis (Peto OR 1.25, 95% CI 0.49 to 3.20). Additionally, no difference was found in the presence of adverse events (Peto OR 1.78, 95% CI 0.18 to 17.48).</P>
<P>Data regarding number of days of hospitalisation are shown in Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. In addition, neither a test for heterogeneity nor subgroup analysis could be performed, as trials could not be combined, and there was not enough information to assess the impact of the intervention, participants, or trial quality. Furthermore, the number of the included trials was too small to allow a funnel plot estimation or a meta-regression analysis to examine potential selection bias.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-14 01:11:20 +0100" MODIFIED_BY="[Empty name]">
<P>In this systematic review we attempted to summarize evidence from randomised clinical trials on the treatment of spontaneous bacterial peritonitis. As with all such analyses, it is important to state that the results are totally dependent on obtaining a reasonable number of trials with low bias risk. Currently, all thirteen identified trials dealt with different comparisons, and an attempt was made to use the results of this review, trying to answer clinical relevant questions in the treatment of spontaneous bacterial peritonitis.</P>
<P>First, we wanted to study whether third generation cephalosporins (particularly cefotaxime) are superior to other antibiotic therapies for spontaneous bacterial peritonitis, and whether these drugs should be regarded as the 'gold-standard' treatment. We found no reliable evidence to place cefotaxime as the 'first choice of treatment' as suggested by many authors in the field (<LINK REF="REF-Arroyo-1994" TYPE="REFERENCE">Arroyo 1994</LINK>; <LINK REF="REF-Bhuva-1994" TYPE="REFERENCE">Bhuva 1994</LINK>; <LINK REF="REF-Rimola-1995a" TYPE="REFERENCE">Rimola 1995a</LINK>; <LINK REF="REF-Guarner-1997" TYPE="REFERENCE">Guarner 1997</LINK>). This assumption was based on the effectiveness of cefotaxime to treat other infectious diseases and on the results of one single trial (<LINK REF="STD-Felisart-1985" TYPE="STUDY">Felisart 1985</LINK>). This trial randomised 73 patients to receive either ampicillin-tobramycin or cefotaxime for the treatment of spontaneous bacterial peritonitis. One should bear in mind, however, that this trial presented some flaws, as no sample size was calculated a priori, deaths that occurred in the first 48 hours were excluded from the final analysis, and follow-up was for only two days after the withdrawal of the antibiotic. This updated review identified four more recent trials comparing third generation cephalosporins with other antibiotics: <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK> compared amikacin versus cefotaxime, <LINK REF="STD-Tuncer-2003" TYPE="STUDY">Tuncer 2003</LINK> compared ciprofloxacin versus cefotaxime or ceftriaxone, and <LINK REF="STD-Angeli--2006" TYPE="STUDY">Angeli 2006</LINK> compared ciprofloxacin versus ceftazidime, and other comparing moxifloxacin versus amoxicillin-clavulanic acid <LINK REF="STD-Grange-2004" TYPE="STUDY">Grange 2004</LINK>. All three trials did not demonstrate any significant advantage for cephalosporins in mortality or resolution of spontaneous bacterial peritonitis. Another two trials compared ceftriaxone with either cefixime (<LINK REF="STD-Figueiredo-1996" TYPE="STUDY">Figueiredo 1996</LINK>) or cefonicid (<LINK REF="STD-Gomez_x002d_Jimenez-1993" TYPE="STUDY">Gomez-Jimenez 1993</LINK>). Both trials, however, were small and no conclusions could be made. Current evidence does not demonstrate superiority of third generation cephalosporins over other antibiotics, but rather equal efficacy. Despite of the new included trials, no substantial changes from the previous review were observed (<LINK REF="REF-Soares_x002d_Weiser-2001" TYPE="REFERENCE">Soares-Weiser 2001</LINK>).</P>
<P>Second, we wanted to study whether oral antibiotic is as effective as intravenous antibiotic to reduce mortality, resolve symptoms of spontaneous bacterial peritonitis, and reduce adverse events. Intravenous third generation cephalosporins were compared with ofloxacin (<LINK REF="STD-Navasa-1996" TYPE="STUDY">Navasa 1996</LINK>), amoxicillin-clavulanic acid (<LINK REF="STD-Ricart-2000" TYPE="STUDY">Ricart 2000</LINK>), or oral third generation cephalosporin (<LINK REF="STD-Figueiredo-1996" TYPE="STUDY">Figueiredo 1996</LINK>) in an attempt to evaluate the cost-effectiveness of oral treatment for spontaneous bacterial peritonitis. An additional trial (<LINK REF="STD-Terg-1997" TYPE="STUDY">Terg 1997</LINK>) compared the effectiveness of intravenous with intravenous + oral ciprofloxacin in the treatment of spontaneous bacterial peritonitis. Additionally, this trial attempted to identify which patients could be treated outside the hospital after a short course of intravenous antibiotic therapy. Once more, each comparison was tested in a single, small trial and should be considered inconclusive. However, it is important to mention that in both trials that tested the use of oral quinolones (<LINK REF="STD-Navasa-1996" TYPE="STUDY">Navasa 1996</LINK>; <LINK REF="STD-Terg-1997" TYPE="STUDY">Terg 1997</LINK>), there was no difference in the effectiveness and mortality for the experimental (oral ofloxacin or IV + oral ciprofloxacin) or control groups (<LINK REF="STD-Navasa-1996" TYPE="STUDY">Navasa 1996</LINK>: IV cefotaxime; <LINK REF="STD-Terg-1997" TYPE="STUDY">Terg 1997</LINK>: IV ciprofloxacin). Although it has been suggested that patients, who present with moderate symptoms or who show a relevant improvement of the symptoms after a short course of intravenous antibiotics, could benefit from this form of treatment (<LINK REF="REF-Arroyo-1994" TYPE="REFERENCE">Arroyo 1994</LINK>; <LINK REF="REF-Rimola-1995a" TYPE="REFERENCE">Rimola 1995a</LINK>; <LINK REF="STD-Navasa-1996" TYPE="STUDY">Navasa 1996</LINK>; <LINK REF="REF-Guarner-1997" TYPE="REFERENCE">Guarner 1997</LINK>; <LINK REF="STD-Terg-1997" TYPE="STUDY">Terg 1997</LINK>): Further research should be planned to compare the effectiveness of intravenous and oral antibiotic in the treatment of spontaneous bacterial peritonitis.<BR/>
<BR/>Third, we wanted to study whether a reduction in the daily dose of intravenous cephalosporin would result in the same effectiveness described with higher dosages. The rationale for this question is based on the fact that cephalosporins are partly metabolised in the liver and acquire high concentration in the ascitic liquid. Therefore, one would expect that the same dose given to cirrhotic patients with ascites would have a prolonged half-life than in a patient with normal liver function. Furthermore, if the decreased dosage of cephalosporins could be achieved without compromising the therapeutic effectiveness, this would result in a reduction of the treatment costs and also have an important impact in resistance to cephalosporins (<LINK REF="STD-Angeli--2006" TYPE="STUDY">Angeli 2006</LINK>). In the single trial that evaluated this question (<LINK REF="STD-Rimola-1995" TYPE="STUDY">Rimola 1995</LINK>) there was a tendency for lower dosages of cefotaxime to cause less death and to resolve the spontaneous bacterial peritonitis symptoms. Although these results go in line with the results described in the literature (<LINK REF="REF-Rimola-1995a" TYPE="REFERENCE">Rimola 1995a</LINK>), no conclusions can be made, and further studies should be planned in order to confirm these initial findings.</P>
<P>Fourth, we wanted to study whether a reduction in the length of treatment would not compromise the effectiveness of antibiotic therapy. Only one study comparing five and ten days of treatment was found (<LINK REF="STD-Runyon-1991" TYPE="STUDY">Runyon 1991</LINK>). It is also important to point out that in all the other trials included in this review, length of treatment was based on the disappearance of signs and symptoms of the disease, and not on a predetermined interval. It is clear that a reduced length of treatment would reduce the cost of spontaneous bacterial peritonitis therapy, but this reduction would only be meaningful if it could be demonstrated that a short-term treatment would not be counterbalanced by a decrease in antibiotic effectiveness.</P>
<P>Finally, whether antibiotic treatment for spontaneous bacterial peritonitis should also cover gram-positive cocci (particularly enterococcus), as up to 10% of infections are caused by these bacteria. This seems to be relevant, particularly as the antibiotic prophylaxis of spontaneous bacterial peritonitis with quinolones has been suggested to increase the number of gram-positive spontaneous bacterial peritonitis in patients resistant to cephalosporins or quinolones (<LINK REF="REF-Guarner-1997" TYPE="REFERENCE">Guarner 1997</LINK>; <LINK REF="STD-Ricart-2000" TYPE="STUDY">Ricart 2000</LINK>). Both ampicillin-tobramycin and amoxicillin-clavulanic acid were used with the assumption that gram-positive spontaneous bacterial peritonitis would be covered; however, no conclusive results are available at this time.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-14 01:15:27 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-10 23:06:06 +0100" MODIFIED_BY="[Empty name]">
<P>Currently, this review provides no clear evidence derived from randomised clinical trials for the treatment of cirrhotic patients with spontaneous bacterial peritonitis. In practice, third generation cephalosporins have already been established as the standard treatment of spontaneous bacterial peritonitis, and it is clear that empirical antibiotic therapy should be provided in any case. However, until large, well-conducted trials provide more information, practice will remain based on impression, not evidence.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-14 01:15:27 +0100" MODIFIED_BY="[Empty name]">
<P>This review has identified several important gaps in our evidence base that warrant future research. For example, the most frequently recommended first-option treatment for spontaneous bacterial peritonitis, cefotaxime and other third generation cephalosporins, lack a robust evidence base. Furthermore, we were unable to answer even one of the main relevant questions that clinicians may face in the day-by-day, when dealing with patients with spontaneous bacterial peritonitis. Currently, it is not possible to decide whether lower dosages or short-term treatment is as effective as higher dosages and long-term treatment, whether oral quinolones should be considered an option for those with less severe manifestations of the disease, and whether antibiotic therapy should also aim to cover enterococci.</P>
<P>Further randomised clinical trials with adequate design, involving a large number of participants and sufficient duration should be carefully planned to provide a more precise estimate of the effects of antibiotic treatment for spontaneous bacterial peritonitis. For example, to answer questions about clinical effectiveness 20% greater than that with the standard treatment, a sample size of at least 268 participants would be needed (90% of power (1-beta), 95% confidence). To assess the impact of different variants of spontaneous bacterial peritonitis in the treatment, much greater numbers would be needed. Any planned trial should also follow up patients for larger period of time, as it has been suggested that spontaneous bacterial peritonitis recurrence and/or liver failure decreases long-term survival in these patients. In addition, this study should take into consideration the possible development of antibiotic resistance, particularly if dealing with quinolones, as these drugs have been widely used in the prophylaxis of spontaneous bacterial peritonitis.</P>
<P>We also suggest that future trials follow recommended guidelines for reporting their results. <LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK> presented guidelines that have been adopted by several leading journals (<A HREF="http://www.consort-statement.org">CONSORT</A> - Consolidated Standards of Reporting Trials). This group developed a checklist of 21 items that include descriptions of the randomisation procedure (allocation concealment), number of people lost during the follow-up and some details about the analysis made. Such descriptions would help evaluating the quality of trials and would benefit when collecting information for systematic reviews.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-11-13 22:11:27 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Figueiredo (Brazil), Grange (France), Terg (Argentina), Runyon (USA), and Angeli (Italy) for the additional information on their trials that they have given to us.</P>
<P>We thank Dimitrinka Nikolova and Christian Gluud of The Cochrane Hepato-Biliary Group for ongoing support for this review.</P>
<P>We thank R.L. Koretz, USA for all the helpful comments on our review.</P>
<P>Contact Editor: C Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-11-13 21:57:14 +0100" MODIFIED_BY="[Empty name]">
<P>Norberto C. Chavez-Tapia: searching, trial selection, data extraction, report writing, and review updating.</P>
<P>Karla Soares-Weiser: protocol writing, searching, trial selection, data extraction and assimilation, report writing, and review updating.</P>
<P>Mayer Brezis: protocol writing, trial selection, data extraction and assimilation, report writing (collaborator during the first version published of this review <LINK REF="REF-Soares_x002d_Weiser-2001" TYPE="REFERENCE">Soares-Weiser 2001</LINK>).</P>
<P>Leonard Leibovici: protocol writing, trial selection, data extraction and assimilation, and report writing (collaborator during the first version published of this review <LINK REF="REF-Soares_x002d_Weiser-2001" TYPE="REFERENCE">Soares-Weiser 2001</LINK>).</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-12 21:55:58 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-11-03 11:30:20 +0100" MODIFIED_BY="Sarah Louise Klingenberg">
<STUDY DATA_SOURCE="PUB" ID="STD-Angeli--2006" NAME="Angeli  2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;&amp;#239;&amp;#187;&amp;#191;1. Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F, et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther. 2006 Jan 1;23(1):75-84.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F, et al</AU>
<TI>Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>1</NO>
<PG>75-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005" NAME="Chen 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;2. Chen TA, Lo GH, Lai KH, Lin WJ. Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics. World J Gastroenterol. 2005 Nov 21;11(43):6823-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen TA, Lo GH, Lai KH, Lin WJ</AU>
<TI>Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotics</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>43</NO>
<PG>6823-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Felisart-1985" MODIFIED="2008-10-09 14:29:44 +0200" MODIFIED_BY="[Empty name]" NAME="Felisart 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-10-09 14:29:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, et al</AU>
<TI>Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections</TI>
<SO>Hepatology</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>3</NO>
<PG>457-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Felisart S, Rimola A, Arroyo V, Rodes J</AU>
<TI>Randomized comparative study of efficacy and nefrotoxicity of ampicilin plus tobromycin versus cefotaxime in cirrhosis with severe infections</TI>
<SO>Hepatology</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>5</NO>
<PG>856</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Figueiredo-1996" NAME="Figueiredo 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Figueiredo FAF, Coelho HSM, Alvariz RG, Silva FD, Godinho F, Salgueiro E</AU>
<TI>Randomized trial comparing intravenous ceftriaxone with oral cefixime for treatment of spontaneous bacterial peritonitis (SBO) in cirrhotic patients: pilot study</TI>
<SO>United European Gastroenterology Week, Paris</SO>
<YR>1996</YR>
<PG>P4 0103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Figueiredo FAF, Coelho HSM, Soares JAS, Salgueiro E, Pinto CA</AU>
<TI>Oral cephalosporin for the treatment of non-severe spontaneous bacterial peritonitis in liver disease: a prospective study of 38 cases</TI>
<TO>Cefalosporina oral para o tratamento da peritonite bacteriana espontanea nao complicada na cirrose hepatica: um estudo prospectivo de 38 casos</TO>
<SO>GED - Gastrenterologia-Endoscopia-Digestiva</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>6</NO>
<PG>231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomez_x002d_Jimenez-1993" MODIFIED="2008-10-09 14:45:51 +0200" MODIFIED_BY="[Empty name]" NAME="Gomez-Jimenez 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-10-09 14:45:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez-Jimenez J, Ribera E, Gasser I, Antaza MA, Del-Valle O, Pahissa A, et al</AU>
<TI>Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1993</YR>
<VL>37</VL>
<NO>8</NO>
<PG>1587-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grange-2004" MODIFIED="2008-11-03 11:30:20 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Grange 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-03 11:30:20 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NOTES="&lt;p&gt;3. Grange J. Randomized, comparative study of moxifloxacin versus amoxicillin-clavulanate in the treatment of bacterial infections in cirrhotic patients. Hepatology. 2004;40(4 (suppl. 1)):631A.&lt;/p&gt;" NOTES_MODIFIED="2008-11-03 11:30:20 +0100" NOTES_MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grange J</AU>
<TI>Randomized, comparative study of moxifloxacin versus amoxicillin-clavulanate in the treatment of bacterial infections in cirrhotic patients</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>4 (Suppl 1)</NO>
<PG>631A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navasa-1996" MODIFIED="2008-10-09 14:56:08 +0200" MODIFIED_BY="[Empty name]" NAME="Navasa 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-09 14:56:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A, et al</AU>
<TI>Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>111</VL>
<NO>4</NO>
<PG>1011-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navasa M, Planas R, Clemente G, Vargas V, Guarner C, Follo A, et al</AU>
<TI>Oral ofloxacin versus intravenous cefotaxime in the treatment of non-complicated spontaneous bacterial peritonitis (SBP) in cirrhosis. Results of a multicenter, prospective, randomized trial</TI>
<SO>Journal of Hepatology</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>S11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ricart-2000" NAME="Ricart 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ricart E, Soriano G, Novella MT, Ortiz J, Sabat M, Kolle L, et al</AU>
<TI>Amoxicillin-clavulinic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>596-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rimola-1984" NAME="Rimola 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grupo Colaborativo para el Estudio de la Peritonitis Bacteriana Espontanea</AU>
<TI>Eficacia de ofloxacino por via oral frente a cefotaxima endovenosa en la peritonitis bacteriana espontanea no complicada. Resultados preliminares de un estudio multicentrico, prospectivo y aleatorizado</TI>
<SO>Gastroenterologia y Hepatologia</SO>
<YR>1994</YR>
<VL>17</VL>
<PG>215</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rimola A, Felisart J, Teres J, et al</AU>
<TI>Estudio controlado de la eficacia terapeutica de dos pautas antibioticas en la peritonitis bacteriana espontanea de la cirrosis: valor prognostico de los datos bacteriologicos</TI>
<SO>Gastroenterologia y Hepatologia</SO>
<YR>1984</YR>
<VL>7</VL>
<NO>5</NO>
<PG>235-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rimola-1995" NAME="Rimola 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rimola A, Salmeron JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, et al</AU>
<TI>Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study</TI>
<SO>Hepatology</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>3</NO>
<PG>674-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spanish Collaborative Group for Study of Spontaneous Bacterial Peritonitis</AU>
<TI>Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Preliminary results of a multicenter, randomized, comparative study</TI>
<SO>Hepatology</SO>
<YR>1992</YR>
<VL>16</VL>
<NO>2</NO>
<PG>594</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiol X, Ariza J</AU>
<TI>Cefotaxime in the treatment of spontaneous bacterial peritonitis [letter; comment]</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>4</NO>
<PG>941-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Runyon-1991" MODIFIED="2008-10-09 15:23:32 +0200" MODIFIED_BY="[Empty name]" NAME="Runyon 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-10-09 15:23:32 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients [see comments]. Gastroenterology 1991; 100(6):1737-42.&lt;/p&gt;" NOTES_MODIFIED="2008-10-09 15:23:32 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA</AU>
<TI>Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients</TI>
<SO>Gastroenterology</SO>
<YR>1991</YR>
<VL>100</VL>
<NO>6</NO>
<PG>1737-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terg-1997" NAME="Terg 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Terg R, Cobas S, Fassio E, Landeira G, Rios B, Vason W, et al</AU>
<TI>Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter randomized study</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>33</VL>
<PG>564-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terg R, Cobas S, Fassio E, Rios B, Vasen W, Abecasis R, et al</AU>
<TI>Oral ciprofloxacin after short-course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: Results of a randomized, multicenter, controlled study</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>Suppl 4</NO>
<PG>557A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terg R, Dobas S, Fassio E, Rios B, Vasen W, Abecasis R</AU>
<TI>Oral ciprofloxacin after short-course of intravenous cirpofloxacin versus intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis. Preliminary results of a randomized controlled study</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>4 Pt 2</NO>
<PG>288A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuncer-2003" NAME="Tuncer 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;5. Tuncer I, Topcu N, Durmus A, Turkdogan MK. Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis. Hepatogastroenterology. 2003 Sep-Oct;50(53):1426-30.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuncer I, Topcu N, Durmus A, Turkdogan MK</AU>
<TI>Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2003</YR>
<VL>50</VL>
<NO>53</NO>
<PG>1426-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-12 21:55:58 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ariza-1991" NAME="Ariza 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ariza J, Xiol X, Esteve M, Fernandez Baneres F, Linares J, Alonso T, et al</AU>
<TI>Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients</TI>
<SO>Hepatology</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>1</NO>
<PG>91-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-2002" NAME="Fernandez 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;&amp;#239;&amp;#187;&amp;#191;1. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002 Jan;35(1):140-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al</AU>
<TI>Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>1</NO>
<PG>140-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fong-1989" NAME="Fong 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Fong TL, Akriviadis EA, Runyon BA, Reynolds TB. Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology 1989; 9(3):423-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fong TL, Akriviadis EA, Runyon BA, Reynolds TB</AU>
<TI>Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis</TI>
<SO>Hepatology</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>3</NO>
<PG>423-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franca-2002" MODIFIED="2008-11-03 11:31:28 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="Franca 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-03 11:31:28 +0100" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>França A, Giordano HM, Sevá-Pereira T, Soares EC</AU>
<TI>Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients</TI>
<SO>Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>37</VL>
<NO>2</NO>
<PG>119-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Llovet--1993" NAME="Llovet  1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;2. Llovet JM, Planas R, Morillas R, Quer JC, Cabre E, Boix J, et al. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol. 1993 Mar;88(3):388-92.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Llovet JM, Planas R, Morillas R, Quer JC, Cabre E, Boix J, et al</AU>
<TI>Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>3</NO>
<PG>388-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCormick-1997" MODIFIED="2008-11-03 11:40:38 +0100" MODIFIED_BY="Sarah Louise Klingenberg" NAME="McCormick 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-03 11:40:38 +0100" MODIFIED_BY="Sarah Louise Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCormick PA, Greenslade L, Kibbler CC, Chin JKT, Burroughs AK, McIntyre N</AU>
<TI>A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>833-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercader-1989" NAME="Mercader 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercader J, Gomez J, Ruiz J, Garre MC, Valdes M</AU>
<TI>Use of ceftriaxone in the treatment of bacterial infections in cirrhotic patients</TI>
<SO>Chemotherapy</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>Suppl 2</NO>
<PG>23-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pariente-1988" NAME="Pariente 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pariente EA, Eid G, Borderon E, Legoux JL</AU>
<TI>Initial antibiotic therapy of spontaneous bacterial peritonitis in cirrhosis: cefotaxime alone vs cefotaxime plus amoxicillin</TI>
<SO>Journal of Hepatology</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>Suppl 1</NO>
<PG>S159</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rastegar-1998" NAME="Rastegar 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rastegar LA, Umrani G, Dehbashi N, Malec F</AU>
<TI>Evaluation of the therapeutic effect of pefloxacin in comparison with ampicillin and gentamicin in cirrhotic patients with spontaneous bacterial peritonitis</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>1998</YR>
<VL>45</VL>
<NO>21</NO>
<PG>783-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sifuentes-1989" NAME="Sifuentes 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Sifuentes-Osornio J, Macias A, Amieva RI, Ramos A, Ruiz-Palacios GM . Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding. Am J Med 1989; 87(5A):202S-5S.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sifuentes-Osornio J, Macias A, Amieva RI, Ramos A, Ruiz-Palacios GM</AU>
<TI>Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding</TI>
<SO>The American Journal of Medicine</SO>
<YR>1989</YR>
<VL>87</VL>
<NO>5A</NO>
<PG>202S-205S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silvain-1989" NAME="Silvain 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silvain C, Breux JP, Grollier G, Rouffineau J, Becq-Giraudon B, Beauchant M</AU>
<TI>Les septicemies et les infections du liquide d'ascite du cirrotique peuvent-elles etre traitees exclusivement par voie orale?</TI>
<SO>Gastroentérologie Clinique et Biologique</SO>
<YR>1989</YR>
<VL>13</VL>
<PG>335-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taskiran--2004" NAME="Taskiran  2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;3. Taskiran B, Colakoglu O, Sozmen B, Unsal B, Aslan SL, Buyrac Z. Comparison of cefotaxime and ofloxacin in treatment of spontaneous bacterial peritonitis. Turk J Gastroenterol. 2004 Mar;15(1):34-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taskiran B, Colakoglu O, Sozmen B, Unsal B, Aslan SL, Buyrac Z</AU>
<TI>Comparison of cefotaxime and ofloxacin in treatment of spontaneous bacterial peritonitis</TI>
<SO>The Turkish Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>1</NO>
<PG>34-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Arroyo-1994" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Arroyo 1994" TYPE="JOURNAL_ARTICLE">
<AU>Arroyo V, Navasa M, Rimola A</AU>
<TI>Spontaneous bacterial peritonitis in liver cirrhosis: treatment and prophylaxis</TI>
<SO>Infection</SO>
<YR>1994</YR>
<VL>22</VL>
<NO>Suppl 3</NO>
<PG>S167-S175</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhuva-1994" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Bhuva 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bhuva M, Ganger D, Jensen D</AU>
<TI>Spontaneous bacterial peritonitis: an update on evolution, management and prevention</TI>
<SO>The American Journal of Medicine</SO>
<YR>1994</YR>
<VL>97</VL>
<PG>169-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castellote-2008" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Castellote 2008" TYPE="JOURNAL_ARTICLE">
<AU>Castellote J, Girbau A, Maisterra S, Charhi N, Ballester R, Xiol X</AU>
<TI>Spontaneous bacterial peritonitis and bacterascites prevalence in asymptomatic cirrhotic outpatients undergoing large-volume paracentesis</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>2</NO>
<PG>256-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chavez_x002d_Tapia-2007" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Chavez-Tapia 2007" TYPE="JOURNAL_ARTICLE">
<AU>Chavez-Tapia NC, Torre-Delgadillo A, Tellez-Avila FI, Uribe M</AU>
<TI>The molecular basis of susceptibility to infection in liver cirrhosis</TI>
<SO>Current Medicinal Chemistry</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>28</NO>
<PG>2954-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fasolato-2007" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Fasolato 2007" TYPE="JOURNAL_ARTICLE">
<AU>Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al</AU>
<TI>Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features</TI>
<SO>Hepatology</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>1</NO>
<PG>223-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franc_x00e9_s-2008" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Francés 2008" TYPE="JOURNAL_ARTICLE">
<AU>Francés R, Zapater P, González-Navajas JM, Muñoz C, Caño R, Moreu R, et al</AU>
<TI>Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis</TI>
<SO>Hepatology</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>3</NO>
<PG>978-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2001" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2001" TYPE="OTHER">
<AU>Gluud C</AU>
<TI>Alcoholic hepatitis: no glucocorticosteroids?</TI>
<SO>FALK Symposium 121. Steatohepatitis (NASH and ASH)</SO>
<YR>2001</YR>
<PG>322-42</PG>
<ED>Leuschner U, James OFW, Dancygier H</ED>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2008" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2008" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als-Nielsen B, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2008, Issue 4. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guarner-1997" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Guarner 1997" TYPE="JOURNAL_ARTICLE">
<AU>Guarner C, Soriano G</AU>
<TI>Spontaneous bacterial peritonitis</TI>
<SO>Seminars in Liver Disease</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>3</NO>
<PG>203-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]</TI>
<SO>The Cochrane Colloboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaymakoglu-1997" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kaymakoglu 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kaymakoglu S, Eraksoy H, Okten A, Demir K, Calangu S, Cakaloglu Y, et al</AU>
<TI>Spontaneous ascitic infection in different cirrhotic groups: prevalence, risk factors and the efficacy of cefotaxime therapy</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>1</NO>
<PG>71-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodological quality and discrepancies between large and small randomised trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuiper-2007" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kuiper 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kuiper JJ, van Buuren HR, de Man RA</AU>
<TI>Review article: Management of ascites and associated complications in patients with cirrhosis</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>Suppl 2</NO>
<PG>183-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leiva-2007" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Leiva 2007" TYPE="JOURNAL_ARTICLE">
<AU>Leiva JG, Salgado JM, Estradas J, Torre A, Uribe M</AU>
<TI>Pathophysiology of ascites and dilutional hyponatremia: contemporary use of aquaretic agents</TI>
<SO>Annals of Hepatology</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>4</NO>
<PG>214-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Obstein-2007" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Obstein 2007" TYPE="JOURNAL_ARTICLE">
<AU>Obstein KL, Campbell MS, Reddy KR, Yang YX</AU>
<TI>Association between model for end-stage liver disease and spontaneous bacterial peritonitis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2007</YR>
<VL>102</VL>
<NO>12</NO>
<PG>2732-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0 for Windows</EN>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rimola-1995a" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Rimola 1995a" TYPE="JOURNAL_ARTICLE">
<AU>Rimola A, Navasa M, Arroyo V</AU>
<TI>Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis</TI>
<SO>Diagnostic Microbiology and Infectious Disease</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>141-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rimola-2000" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Rimola 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al</AU>
<TI>Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>1</NO>
<PG>142-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thanapoulou-2002" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Thanapoulou 2002" TYPE="JOURNAL_ARTICLE">
<AU>Thanopoulou AC, Koskinas JS, Hadziyannis SJ</AU>
<TI>Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience</TI>
<SO>European Journal of Internal Medicine</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>3</NO>
<PG>194-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thuluvath-2001" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Thuluvath 2001" TYPE="JOURNAL_ARTICLE">
<AU>Thuluvath PJ, Morss S, Thompson R</AU>
<TI>Spontaneous bacterial peritonitis - in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>96</VL>
<NO>4</NO>
<PG>1232-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2005" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2005" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>WHO Draft Guidelines for adverse event reporting and learning systems</SO>
<YR>2005</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Soares_x002d_Weiser-2001" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NAME="Soares-Weiser 2001" TYPE="COCHRANE_REVIEW">
<AU>Soares-Weiser K, Brezis M, Leibovici L</AU>
<TI>Antibiotics for spontaneous bacterial peritonitis in cirrhotics</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-07-23 11:04:51 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-23 11:04:48 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002232"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-14 01:21:02 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-14 01:21:02 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-13 16:04:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Angeli--2006">
<CHAR_METHODS MODIFIED="2008-10-26 19:00:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: Sealed envelopes prepared with random numbers generated by software.<BR/>Blinding: none.<BR/>Intention-to-treat: yes.<BR/>Interim analysis: no.<BR/>Exclusions from analysis: none.<BR/>Follow-up period: until death, liver transplantation or 3 months following inclusion.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 16:04:52 +0100" MODIFIED_BY="[Empty name]">
<P>Italy.<BR/>Spontaneous bacterial peritonitis confirmed by ascitic fluid PMN count &gt;250 cells/mm<SUP>3</SUP>.<BR/>Stage of cirrhosis determined by Chil-Pugh and MELD score.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:00:50 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: IV ceftazidime (2 grams bid, 1 gram bid or 1 gram once daily according to level of creatinine).<BR/>Control: IV ciprofloxacin 200 mg bid or once daily if creatinine &gt;2.5 mg/dL.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 23:03:57 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolutions.<BR/>Number of superinfections.<BR/>Number of recurrences.<BR/>Severe adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-13 15:54:18 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with type 1 hepatorenal syndrome were treated with terlipressin and albumin.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-14 01:17:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005">
<CHAR_METHODS MODIFIED="2008-10-26 19:01:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: Methods not described.<BR/>Blinding: none.<BR/>Intention-to-treat: no.<BR/>Interim analysis: no.<BR/>Exclusions from analysis: 8/45 randomised patients, 2 in the amikacin group due to secondary peritonitis, 3 in each group due to death or refusal within 48 hours.<BR/>Follow-up period: 4 weeks after antibiotic discontinuation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-14 01:17:23 +0100" MODIFIED_BY="[Empty name]">
<P>Taiwan spontaneous bacterial peritonitis confirmed by ascitic fluid PMN count &gt; 500 cells/mm<SUP>3.</SUP>
</P>
<P>Stage of cirrhosis not determined.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-14 01:17:33 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: IV cefotaxime (1 g four times a day).</P>
<P>Control: IV amikacin 500 mg once daily or 8 mg/kg once daily if weight &lt; 60 kg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 23:03:59 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis cures.<BR/>Number of afebrile patients.<BR/>Number of superinfections.<BR/>Number of recurrences.<BR/>Days of hospitalisation.<BR/>Nephrotoxicity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-13 15:55:43 +0100" MODIFIED_BY="[Empty name]">
<P>The dosage of amikacin was adjusted according to plasma levels.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-13 15:56:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Felisart-1985">
<CHAR_METHODS MODIFIED="2008-11-13 11:12:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: table of random number, no further information.<BR/>Blinding: none.<BR/>Intention-to-treat: no.<BR/>Interim analysis: yes, abstract with data from 69 patients with similar results.<BR/>Exclusions from analysis: 8/73 randomised patients.<BR/>Follow-up period: up to 2 days after antibiotic withdrawal.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 15:56:09 +0100" MODIFIED_BY="[Empty name]">
<P>Spain.<BR/>Spontaneous bacterial peritonitis, UTI, and bacteraemia confirmed by positive culture. </P>
<P>Stage of cirrhosis: not determined.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 11:16:32 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: IV cefotaxime 2g every 6 or 8 hs (according to creatinine clearance).<BR/>Control: IV tobramycin, 1.75 mg/kg every 8 hs + ampicillin, 2g every 6 or 8 hs (according to creatinine clearance).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 23:50:38 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolutions.<BR/>Number of therapeutic failures.<BR/>Number of superinfections.<BR/>Nephrotoxicity.<BR/>Number of adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-13 11:50:53 +0100" MODIFIED_BY="[Empty name]">
<P>The dosages of tobramycin and ampicillin were adjusted according to renal function.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-13 22:12:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Figueiredo-1996">
<CHAR_METHODS MODIFIED="2008-11-13 22:12:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: Random numbers generated by computer software.<BR/>Blinding: not blinded trial.<BR/>Intention-to-treat: no information.<BR/>Interim analysis: no information.<BR/>Exclusion from analysis: no information.<BR/>Follow-up period: up to 2 days after antibiotic withdrawal.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 16:05:08 +0100" MODIFIED_BY="[Empty name]">
<P>Brazil.<BR/>Spontaneous bacterial peritonitis confirmed by ascitic fluid PMN &gt; 250cells/mm<SUP>3</SUP>.<BR/>Stage of cirrhosis determined by Child-Pugh score.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:04:42 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: oral cefixime, 400 mg every 24 hs.<BR/>Control: IV ceftriaxone, 1g every 12 hs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 11:22:58 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolution.<BR/>Treatment duration.<BR/>Costs.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-26 19:05:01 +0100" MODIFIED_BY="[Empty name]">
<P>Data and details of randomisation provided by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-13 16:05:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gomez_x002d_Jimenez-1993">
<CHAR_METHODS MODIFIED="2008-11-13 11:33:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: method not described.<BR/>Blinding: none.<BR/>Intention-to-treat: no.<BR/>Interim analysis: no information.<BR/>Exclusion from analysis: 7/60 randomised patients who died in the first 48 hs were considered therapeutic failure and excluded.<BR/>Follow-up period: 10 days or 4 days after becoming afebrile.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 16:05:15 +0100" MODIFIED_BY="[Empty name]">
<P>Spain.<BR/>Spontaneous bacterial peritonitis confirmed by positive ascitic culture and ascitic fluid PMN &gt; 250cells/mm<SUP>3</SUP>.<BR/>Stage of cirrhosis determined by Child-Pugh score.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:05:47 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: IV cefonicid, 2 g every 12 hs.<BR/>Control: IV ceftriaxone, 2 g once a day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 23:04:09 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolution.<BR/>Number of therapeutic failure.<BR/>Number of superinfection.<BR/>Number of adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-13 11:35:58 +0100" MODIFIED_BY="[Empty name]">
<P>One patient died with anaphylactic shock after the first dose of cefonicid.</P>
<P>This trial was supported by a government grant.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-13 11:40:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grange-2004">
<CHAR_METHODS MODIFIED="2008-11-13 11:40:11 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: methods not described.<BR/>Blinding: none.<BR/>Intention-to-treat: yes.<BR/>Interim analysis: no.<BR/>Exclusions from analysis: none.</P>
<P>Follow-up period: last follow-up visit (21 to 31 days after end of therapy).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-10 23:52:39 +0100" MODIFIED_BY="[Empty name]">
<P>France.<BR/>Spontaneous bacterial peritonitis and UTI confirmation not reported.<BR/>Stage of cirrhosis not determined.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: IV/PO moxifloxacin (400 mg once daily).<BR/>Control: PO/IV amoxicillin-clavulanate 1200 mg IV or 625 mg PO three times a day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 23:04:11 +0100" MODIFIED_BY="[Empty name]">
<P>Number of spontaneous bacterial peritonitis resolution.<BR/>Hepatic failure or damage.<BR/>QT interval prolongation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-10 23:04:13 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with spontaneous bacterial peritonitis received IV albumin.</P>
<P>Some data provided by the author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-13 16:05:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Navasa-1996">
<CHAR_METHODS MODIFIED="2008-11-13 11:46:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: multicenter, central telephone randomisation, sealed envelopes with random numbers.<BR/>Blinding: none.<BR/>Intention-to-treat: yes.<BR/>Interim analysis: no information.<BR/>Exclusion from analysis: no.<BR/>Follow-up period: no information, duration of treatment from 4 to 14 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 16:05:23 +0100" MODIFIED_BY="[Empty name]">
<P>Spain.<BR/>Spontaneous bacterial peritonitis confirmed by positive ascitic culture and ascitic fluid PMN &gt; 250cells/mm<SUP>3</SUP>.<BR/>Stage of cirrhosis: not determined.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:08:49 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: oral ofloxacin, 400 mg every 12 hs.<BR/>Control: IV cefotaxime, 2g every 6 hs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 23:04:15 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolution.<BR/>Number of therapeutic failure.<BR/>Number of superinfections.<BR/>Number of adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-26 19:08:59 +0100" MODIFIED_BY="[Empty name]">
<P>The dosages of ofloxacin and cefotaxime were adjusted according to renal function.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-14 01:21:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ricart-2000">
<CHAR_METHODS MODIFIED="2008-11-13 16:00:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: method not described.<BR/>Blinding: none.<BR/>Intention-to-treat: yes.<BR/>Interim analysis: performed after inclusion of 1/3 of the patients.<BR/>Exclusion from analysis: 48 patients were excluded because other than spontaneous bacterial peritonitis was the source infection.<BR/>Follow-up period: until resolution of infection (5 to 12 days).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-14 01:21:02 +0100" MODIFIED_BY="[Empty name]">
<P>Spain.<BR/>Spontaneous bacterial peritonitis confirmed by positive ascitic culture and ascitic fluid PMN &gt; 250cells/mm<SUP>3</SUP>.<BR/>Stage of cirrhosis determined by Child-Pugh score.<BR/>Other bacterial infections: UTI, bacteraemia and pneumonia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:09:54 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: amoxicillin-clavulanic acid, IV: 1g-0.2g every 8hs; Oral: 500mg-125mg every 8hs.<BR/>Control: IV cefotaxime, 1g every 6 hs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 11:57:25 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolution.<BR/>Number of bacterial infection resolution.<BR/>Number of therapeutic failure.<BR/>Average length of hospitalisation.<BR/>Number of adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-13 15:59:45 +0100" MODIFIED_BY="[Empty name]">
<P>The dosages of amoxicillin-clavulanic acid and cefotaxime were adjusted according to renal function.<BR/>Patients were stratified according to previous prophylaxis with norfloxacin.<BR/>Bacteria resistance was stated to happen in those previously treated with norfloxacin.</P>
<P>The analysis was made with data of patients with spontaneous bacterial peritonitis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-13 16:05:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rimola-1984">
<CHAR_METHODS MODIFIED="2008-10-26 19:10:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: method not described.<BR/>Blinding: none.<BR/>Intention-to-treat: no information.<BR/>Interim analysis: no information.<BR/>Exclusions from analysis: 4/37 randomised patients, all died after randomisation.<BR/>Follow-up period: up to 2 days after antibiotic withdrawal.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 16:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>Spain.<BR/>Spontaneous bacterial peritonitis confirmed by positive ascitic culture and ascitic fluid PMN &gt; 1000cells/mm<SUP>3</SUP>.<BR/>Stage of cirrhosis: not determined.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:11:15 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: IV tobramycin, 2 mg/kg every 8 hs + ampicillin, 2g every 4 hs + neomicin, 1g + colistin, 1.5 x 10 6 U + nistatin, 10 6 U.<BR/>Control: IV tobramycin, 2 mg/kg every 8 hs + ampicillin, 2g every 4 hs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 23:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolution.<BR/>Number of adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-13 12:04:17 +0100" MODIFIED_BY="[Empty name]">
<P>The dosages of tobramycin and ampicillin were adjusted according to creatinine clearance.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-13 16:05:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rimola-1995">
<CHAR_METHODS MODIFIED="2008-10-26 19:11:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: multicenter, randomisation made separately in each hospital, method not described.<BR/>Blinding: none.<BR/>Intention-to-treat: yes.<BR/>Interim analysis: yes, abstract with data from 93 patients with similar results.<BR/>Exclusions from analysis: 7/143 randomised patients, all died after randomisation.<BR/>Follow-up period: no information.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 16:05:43 +0100" MODIFIED_BY="[Empty name]">
<P>Spain.<BR/>Spontaneous bacterial peritonitis confirmed by positive ascitic culture and ascitic fluid PMN &gt; 250cells/mm<SUP>3</SUP>.<BR/>Stage of cirrhosis determined by Child-Pugh score.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:12:11 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: IV cefotaxime, 2 g every 12 hs.<BR/>Control: IV cefotaxime, 2 g every 6 hs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 23:04:21 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolution.<BR/>Number of therapeutic failure.<BR/>Number of superinfections.<BR/>Number of adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-26 19:12:28 +0100" MODIFIED_BY="[Empty name]">
<P>An early abstract published in 1992 states that the number of patients to be randomised would be 452 (only 143 patients are described in the trial).<BR/>The dosages of cefotaxime in both groups were adjusted according to renal function.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-13 22:02:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Runyon-1991">
<CHAR_METHODS MODIFIED="2008-11-13 22:02:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: multicenter, sealed opaque envelopes.<BR/>Blinding: none.<BR/>Intention-to-treat: no.<BR/>Interim analysis: no information.<BR/>Exclusion from analysis: 10/100 randomised patients.<BR/>Follow-up period: until death or last known encounter. <BR/>Sample size calculation: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 16:05:51 +0100" MODIFIED_BY="[Empty name]">
<P>USA.<BR/>Spontaneous bacterial peritonitis confirmed by positive ascitic culture and ascitic fluid PMN &gt; 250cells/mm<SUP>3</SUP> (61 patients); culture-negative neutrocytic ascites (29 patients).<BR/>Stage of cirrhosis determined by Child-Pugh score.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:13:53 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: IV cefotaxime, 2 g every 8 hs for 5 days (15 doses).<BR/>Control: IV cefotaxime, 2 g every 8 hs for 10 days (30 doses).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 12:19:23 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolution.<BR/>Number of therapeutic failure.<BR/>Number of superinfections.<BR/>Number of re-infections.<BR/>Number of adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-13 12:22:43 +0100" MODIFIED_BY="[Empty name]">
<P>18 patients (7 in short-course and 11 in long course) required at least another antibiotic for the treatment.</P>
<P>The trial was supported in part by a grant from Hoechst-Roussel Pharmaceuticals, Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-13 16:06:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terg-1997">
<CHAR_METHODS MODIFIED="2008-10-26 19:23:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: multicenter, table of random numbers, independently done by each centre.<BR/>Blinding: none.<BR/>Intention-to-treat: yes.<BR/>Interim analysis: no information.<BR/>Exclusion from analysis: only for efficacy analysis 5/80 patients were excluded because of death in the first 48 hs.<BR/>Follow-up period: 7 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 16:06:05 +0100" MODIFIED_BY="[Empty name]">
<P>Argentina.<BR/>Spontaneous bacterial peritonitis confirmed by positive ascitic culture and ascitic fluid PMN &gt; 250cells/mm<SUP>3</SUP>.</P>
<P>Stage of cirrhosis determined by Child-Pugh score.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:24:10 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: IV + oral ciprofloxacin, 200 mg every 12 hs for two days + 500 mg every 12 hs for 5 days.<BR/>Control: IV ciprofloxacin, 200 mg every 12 hs for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 12:27:50 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolution.<BR/>Number of therapeutic failure.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-26 19:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>Some data provided by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-13 16:07:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tuncer-2003">
<CHAR_METHODS MODIFIED="2008-10-26 19:24:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation: method not described.<BR/>Blinding: none.<BR/>Intention-to-treat: no.<BR/>Interim analysis: no information.<BR/>Exclusion from analysis: 4/53 patients were excluded because of death during therapy.<BR/>Follow-up period: no information, duration of treatment 5 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 16:07:12 +0100" MODIFIED_BY="[Empty name]">
<P>Turkey.<BR/>Spontaneous bacterial peritonitis confirmed by ascitic fluid PMN &gt; 250cells/mm<SUP>3</SUP>.</P>
<P>Stage of cirrhosis determined by Child-Pugh score.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-26 19:25:10 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental: Group A - oral ciprofloxacin, 500 mg every 12 hs for 5 days, Group B - IV cefotaxime 2 g every 8 hs for 5 days.<BR/>Control: Group C - IV Ceftriaxone 2 g daily for 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 12:41:19 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality.<BR/>Number of spontaneous bacterial peritonitis resolution.<BR/>Number of therapeutic failure.<BR/>Complication.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IV - intravenous.<BR/>UTI - urinary tract infection.<BR/>hs - hours.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-13 16:04:20 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-12 21:23:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ariza-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-12 21:23:28 +0100" MODIFIED_BY="[Empty name]">
<P>Spain.<BR/>Quasi-RCT.<BR/>The original protocol is a randomised controlled trial, but in the group of patients treated with aztreonam (26 patients), 17 received concomitantly penicillin, and 4 received vancomicin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-26 19:25:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fernandez-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-26 19:25:48 +0100" MODIFIED_BY="[Empty name]">
<P>Spain.<BR/>Prospective, not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-26 19:25:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fong-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-26 19:25:50 +0100" MODIFIED_BY="[Empty name]">
<P>USA.<BR/>Prospective (follow-up) study, not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-26 19:25:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Franca-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-26 19:25:58 +0100" MODIFIED_BY="[Empty name]">
<P>Brazil.</P>
<P>Prospective, not randomised, not comparative trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-26 19:26:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Llovet--1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-26 19:26:00 +0100" MODIFIED_BY="[Empty name]">
<P>Spain.<BR/>Prospective, not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-12 21:41:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCormick-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-12 21:41:02 +0100" MODIFIED_BY="[Empty name]">
<P>UK.<BR/>RCT on sepsis and cirrhosis<BR/>11/128 patients had infection of the ascitic fluid, and no specific information was provided for this sub-group of patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-26 19:26:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mercader-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-26 19:26:11 +0100" MODIFIED_BY="[Empty name]">
<P>Spain.<BR/>Prospective (follow up) study, not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-26 19:26:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pariente-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-26 19:26:13 +0100" MODIFIED_BY="[Empty name]">
<P>France.<BR/>Prospective, no information on the abstract about methodological design. Authors contact, but did not reply within one year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-12 21:51:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rastegar-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-12 21:51:19 +0100" MODIFIED_BY="[Empty name]">
<P>Iran.<BR/>Quasi-RCT.<BR/>Inadequate allocation concealment, 2/9 patients were transferred from one group to another after randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-13 16:04:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sifuentes-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-13 16:04:20 +0100" MODIFIED_BY="[Empty name]">
<P>Mexico.<BR/>Quasi-RCT on serious infections and cirrhosis.<BR/>Treatment of severe bacterial infections, only 5/59 patients had spontaneous bacterial peritonitis.<BR/>No information about the primary diagnosis of the 11 patients who dropped out before end of study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-26 19:26:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silvain-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-26 19:26:29 +0100" MODIFIED_BY="[Empty name]">
<P>France.<BR/>Prospective (follow-up) study, not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-26 19:26:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taskiran--2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-26 19:26:34 +0100" MODIFIED_BY="[Empty name]">
<P>Turkey.<BR/>Prospective study, not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT - randomised controlled trial<BR/>IV - intravenous<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-11-14 01:26:36 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-11-13 22:07:08 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:01:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angeli--2006">
<DESCRIPTION>
<P>Sequence generated by computer software.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:24:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:03:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>Table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:05:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Figueiredo-1996">
<DESCRIPTION>
<P>Random numbers generated by computer software.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:33:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez_x002d_Jimenez-1993">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:08:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grange-2004">
<DESCRIPTION>
<P>Information not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 22:00:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navasa-1996">
<DESCRIPTION>
<P>Central telephone randomisation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:58:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ricart-2000">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:04:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rimola-1984">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:14:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rimola-1995">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 22:07:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Runyon-1991">
<DESCRIPTION>
<P>Central.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:24:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Terg-1997">
<DESCRIPTION>
<P>Table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 16:03:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-2003">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-11-13 22:00:49 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 10:50:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angeli--2006">
<DESCRIPTION>
<P>Using sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:24:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:24:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:23:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Figueiredo-1996">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:33:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez_x002d_Jimenez-1993">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:08:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grange-2004">
<DESCRIPTION>
<P>Information not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 22:00:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navasa-1996">
<DESCRIPTION>
<P>Sealed envelopes with random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:58:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ricart-2000">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:04:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rimola-1984">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:14:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rimola-1995">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:26:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Runyon-1991">
<DESCRIPTION>
<P>Sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 16:03:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Terg-1997">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 16:03:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-2003">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-11-13 16:03:28 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-26 19:01:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Angeli--2006">
<DESCRIPTION>
<P>The trial was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-26 19:02:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>The protocol dosages impede the blinding for the investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-26 19:03:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>The protocol dosages impede the blinding for the investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-26 19:05:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Figueiredo-1996">
<DESCRIPTION>
<P>The trial was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-26 19:06:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gomez_x002d_Jimenez-1993">
<DESCRIPTION>
<P>The trials was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-26 19:08:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Grange-2004">
<DESCRIPTION>
<P>The protocol dosages impede the blinding for the investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-26 19:09:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Navasa-1996">
<DESCRIPTION>
<P>The protocol dosages impede the blinding for the investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-26 19:10:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ricart-2000">
<DESCRIPTION>
<P>The protocol dosages impede the blinding for the investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-13 12:06:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rimola-1984">
<DESCRIPTION>
<P>The protocol dosages impede the blinding for the investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-13 12:13:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rimola-1995">
<DESCRIPTION>
<P>The protocol dosages impede the blinding for the investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-26 19:14:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Runyon-1991">
<DESCRIPTION>
<P>Not blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-26 19:24:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terg-1997">
<DESCRIPTION>
<P>The protocol dosages impede the blinding for the investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-13 16:03:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tuncer-2003">
<DESCRIPTION>
<P>No blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-11-13 16:03:46 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-10-26 19:01:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angeli--2006">
<DESCRIPTION>
<P>There were no post-randomisation drop-outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-13 11:04:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>There were 8 post-randomisation drop-outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-13 11:17:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>There were 8 post-randomisation drop-outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-13 11:24:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Figueiredo-1996">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-13 11:33:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gomez_x002d_Jimenez-1993">
<DESCRIPTION>
<P>There were 7 post-randomisation drop-outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-10-26 19:08:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grange-2004">
<DESCRIPTION>
<P>There were no post-randomisation drop-outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-10-26 19:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navasa-1996">
<DESCRIPTION>
<P>There were no post-randomisation drop-outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-13 12:01:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ricart-2000">
<DESCRIPTION>
<P>There were no post-randomisation drop-outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-13 12:05:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rimola-1984">
<DESCRIPTION>
<P>Four patients were excluded after randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-13 12:21:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rimola-1995">
<DESCRIPTION>
<P>There were reported 7 post-randomisation drop-outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-13 12:21:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Runyon-1991">
<DESCRIPTION>
<P>There were reported 10 post-randomisation drop-outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-13 12:35:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terg-1997">
<DESCRIPTION>
<P>There were reported 5 post-randomisation drop-outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-13 16:03:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tuncer-2003">
<DESCRIPTION>
<P>There is exclusion of dead patients from the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-11-13 12:34:22 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:01:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angeli--2006">
<DESCRIPTION>
<P>All the important outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:02:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>All the important outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:17:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>All the important outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:25:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Figueiredo-1996">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:06:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gomez_x002d_Jimenez-1993">
<DESCRIPTION>
<P>All the important outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:41:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Grange-2004">
<DESCRIPTION>
<P>Some relevant outcomes were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:09:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navasa-1996">
<DESCRIPTION>
<P>All the important outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:01:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ricart-2000">
<DESCRIPTION>
<P>All the important outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:04:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rimola-1984">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:12:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rimola-1995">
<DESCRIPTION>
<P>All the important outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:23:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Runyon-1991">
<DESCRIPTION>
<P>All the important outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:34:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terg-1997">
<DESCRIPTION>
<P>Information about adverse events was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:25:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tuncer-2003">
<DESCRIPTION>
<P>All the important outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-11-14 01:26:36 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 10:52:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angeli--2006">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-26 19:02:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:19:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>The trial perform interim analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:25:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Figueiredo-1996">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:34:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez_x002d_Jimenez-1993">
<DESCRIPTION>
<P>Is unclear if an interim analysis was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:42:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grange-2004">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:52:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Navasa-1996">
<DESCRIPTION>
<P>Is unclear if an interim analysis was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-14 01:24:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ricart-2000">
<DESCRIPTION>
<P>Interim analysis was performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:04:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rimola-1984">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-14 01:23:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rimola-1995">
<DESCRIPTION>
<P>Interim analysis was performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 16:02:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Runyon-1991">
<DESCRIPTION>
<P>Is unclear if an interim analysis was done, and the trial was sponsored by industry.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-14 01:26:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Terg-1997">
<DESCRIPTION>
<P>Is unclear if an interim analysis was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:41:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-2003">
<DESCRIPTION>
<P>Is unclear if an interim analysis was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2008-11-13 16:03:32 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Follow-up?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 10:52:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angeli--2006">
<DESCRIPTION>
<P>All patients randomised were followed until death, liver transplantation, or until 3 months after inclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:06:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>All patients discharged alive were followed up to 4 weeks after completion of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 15:56:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Felisart-1985">
<DESCRIPTION>
<P>All survivors, up to 2 days after antibiotic withdrawal.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:25:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Figueiredo-1996">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:34:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomez_x002d_Jimenez-1993">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:42:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grange-2004">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 11:53:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Navasa-1996">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:02:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ricart-2000">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:04:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rimola-1984">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:14:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rimola-1995">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:25:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Runyon-1991">
<DESCRIPTION>
<P>Not all patients were followed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 12:35:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terg-1997">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-13 16:03:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-2003">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-11 00:45:24 +0100" MODIFIED_BY="[Empty name]">Mean number of days of hospitalisation</TITLE>
<TABLE COLS="5" ROWS="4">
<TR>
<TD>
<P>Study</P>
</TD>
<TH>
<P>Mean (T)</P>
</TH>
<TH>
<P>SD (T)</P>
</TH>
<TH>
<P>Mean (C)</P>
</TH>
<TH>
<P>SD (C)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Terg-1997" TYPE="STUDY">Terg 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>17</P>
</TD>
<TD ALIGN="CENTER">
<P>6</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD ALIGN="CENTER">
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ricart-2000" TYPE="STUDY">Ricart 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>18.4</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>17</P>
</TD>
<TD ALIGN="CENTER">
<P>7.1</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>13</P>
</TD>
<TD ALIGN="CENTER">
<P>9</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-13 15:30:52 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-13 15:24:27 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Ampicillin-tobramycin-neomycin-nystatin-colistin versus ampicillin-tobramycin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.456757773036204" CI_START="0.5810800017884173" EFFECT_SIZE="2.08157940518532" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.8725500356020689" LOG_CI_START="-0.23576407080522643" LOG_EFFECT_SIZE="0.3183929823984212" ORDER="6" O_E="1.7297297297297298" SE="0.6510291923469529" STUDY_ID="STD-Rimola-1984" TOTAL_1="18" TOTAL_2="19" VAR="2.3593864134404674" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:02:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.127875026091257" CI_START="0.574177537044684" EFFECT_SIZE="2.52772147892566" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.0464122395771134" LOG_CI_START="-0.24095380196205965" LOG_EFFECT_SIZE="0.4027292188075268" ORDER="7" O_E="1.621621621621622" SE="0.7562051853647912" STUDY_ID="STD-Rimola-1984" TOTAL_1="18" TOTAL_2="19" VAR="1.7487216946676407" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-11-13 15:24:27 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Cefotaxime versus ampicillin-tobramycin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.135650945554164" CI_START="0.5942836463570264" EFFECT_SIZE="1.5677211882167734" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.6165438766001918" LOG_CI_START="-0.2260062205993085" LOG_EFFECT_SIZE="0.19526882800044162" ORDER="1" O_E="1.8356164383561637" SE="0.49491809778523166" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="4.082567085757177" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-12 22:45:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8670414332574697" CI_START="0.1312749714065825" EFFECT_SIZE="0.3373734419885428" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" LOG_CI_END="-0.06196014842328818" LOG_CI_START="-0.8818180676359524" LOG_EFFECT_SIZE="-0.47188910802962025" MODIFIED="2008-11-12 22:45:37 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="-4.684931506849315" SE="0.48158860010767146" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="4.311690748733346" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-07-23 15:45:34 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Fatal adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.636057486743831" CI_START="0.0026108652721115126" EFFECT_SIZE="0.13162770238773855" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8219101395686417" LOG_CI_START="-2.5832155383984965" LOG_EFFECT_SIZE="-0.8806526994149275" ORDER="3" O_E="-0.5068493150684932" SE="2.000187678881847" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="0.2499530868830925" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-07-23 15:45:34 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Any adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8269301130478173" CI_START="0.4142218747674679" EFFECT_SIZE="1.0821165793311167" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.4513150720576625" LOG_CI_START="-0.3827669700491494" LOG_EFFECT_SIZE="0.0342740510042566" ORDER="4" O_E="0.32876712328767077" SE="0.48994392030623773" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="4.165884781384875" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-07-23 15:45:34 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Lost of follow-up before end of study</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.172039986774082" CI_START="0.2255728793217752" EFFECT_SIZE="0.9701026092440997" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6203484622549992" LOG_CI_START="-0.6467131168736582" LOG_EFFECT_SIZE="-0.013182327309329549" ORDER="5" O_E="-0.054794520547945424" SE="0.7442782436361444" STUDY_ID="STD-Felisart-1985" TOTAL_1="37" TOTAL_2="36" VAR="1.8052167386001126" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-11-13 15:26:56 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Short-term cefotaxime versus long-term cefotaxime</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5339605555208078" CI_START="0.28116229281743604" EFFECT_SIZE="0.6567281529535172" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.18581419224666412" LOG_CI_START="-0.5510429237637906" LOG_EFFECT_SIZE="-0.1826143657585632" ORDER="28" O_E="-2.2444444444444436" SE="0.43283351744609155" STUDY_ID="STD-Runyon-1991" TOTAL_1="43" TOTAL_2="47" VAR="5.337750034678874" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:05:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.707177017869756" CI_START="0.4855031313131223" EFFECT_SIZE="1.1464479574732935" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.4325166545036129" LOG_CI_START="-0.3138079647104055" LOG_EFFECT_SIZE="0.05935434489660363" ORDER="29" O_E="0.7111111111111104" SE="0.4383947756927614" STUDY_ID="STD-Runyon-1991" TOTAL_1="43" TOTAL_2="47" VAR="5.2031849077541965" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:05:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.160782317762151" CI_START="0.2565019598689887" EFFECT_SIZE="0.9004148261913707" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4997945871239702" LOG_CI_START="-0.5909093122011502" LOG_EFFECT_SIZE="-0.04555736253858998" ORDER="30" O_E="-0.25555555555555554" SE="0.6406848695349524" STUDY_ID="STD-Runyon-1991" TOTAL_1="43" TOTAL_2="47" VAR="2.4361894853655155" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-07-23 16:03:21 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Any adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.45066596706839" CI_START="0.21940261295644375" EFFECT_SIZE="2.1694082517660584" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3314407800327788" LOG_CI_START="-0.6587582045379367" LOG_EFFECT_SIZE="0.33634128774742106" ORDER="31" O_E="0.5666666666666667" SE="1.1690527351806972" STUDY_ID="STD-Runyon-1991" TOTAL_1="43" TOTAL_2="47" VAR="0.7316978776529338" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-11-13 15:27:59 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>IV Cefonicid versus IV ceftriaxone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-12 23:14:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.894373918997543" CI_START="0.4632293798491298" EFFECT_SIZE="1.3431263586862767" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.590437648047152" LOG_CI_START="-0.3342039037242334" LOG_EFFECT_SIZE="0.12811687216145928" MODIFIED="2008-11-12 23:14:25 +0100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="1.0" SE="0.5431390245600108" STUDY_ID="STD-Gomez_x002d_Jimenez-1993" TOTAL_1="30" TOTAL_2="30" VAR="3.389830508474576" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:04:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="79.2580798474003" CI_START="0.7926619155333293" EFFECT_SIZE="7.926213559659736" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.899043546653485" LOG_CI_START="-0.10091200754528452" LOG_EFFECT_SIZE="0.8990657695541002" ORDER="19" O_E="1.5" SE="1.1747837924760145" STUDY_ID="STD-Gomez_x002d_Jimenez-1993" TOTAL_1="30" TOTAL_2="30" VAR="0.7245762711864407" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-07-23 15:57:52 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Fatal adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="20" O_E="0.5" SE="2.0" STUDY_ID="STD-Gomez_x002d_Jimenez-1993" TOTAL_1="30" TOTAL_2="30" VAR="0.25" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-12 23:14:15 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Any adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.476599925822147" CI_START="0.1337506366425026" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8737041420942644" LOG_CI_START="-0.8737041420942644" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-12 23:14:15 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.026436275942851" STUDY_ID="STD-Gomez_x002d_Jimenez-1993" TOTAL_1="30" TOTAL_2="30" VAR="0.9491525423728814" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-12 23:07:19 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Lost of follow-up before end of study</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.717953596156375" CI_START="0.40295359761323335" EFFECT_SIZE="1.7635127353617848" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8875021630674834" LOG_CI_START="-0.39474496244648627" LOG_EFFECT_SIZE="0.24637860031049863" ORDER="23" O_E="1.0" SE="0.7531983087525438" STUDY_ID="STD-Gomez_x002d_Jimenez-1993" TOTAL_1="30" TOTAL_2="30" VAR="1.7627118644067796" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-11-13 15:27:59 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>IV low dose cefotaxime (every 12 hours) versus IV high dose cefotaxime (every 6 hours)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="72" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2463901010587992" CI_START="0.2803985452463055" EFFECT_SIZE="0.5911733850117772" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.09565399113672746" LOG_CI_START="-0.5522242438906177" LOG_EFFECT_SIZE="-0.22828512637694517" ORDER="24" O_E="-3.62937062937063" SE="0.3805668823040486" STUDY_ID="STD-Rimola-1995" TOTAL_1="72" TOTAL_2="71" VAR="6.9045919115849195" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-12 23:29:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="72" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1917862343446814" CI_START="0.44048924358717734" EFFECT_SIZE="0.982577355973196" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.34079819498952035" LOG_CI_START="-0.35606469226389725" LOG_EFFECT_SIZE="-0.007633248637188418" MODIFIED="2008-11-12 23:29:39 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="-0.104895104895105" SE="0.4093407094995827" STUDY_ID="STD-Rimola-1995" TOTAL_1="72" TOTAL_2="71" VAR="5.968017995990024" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-12 23:19:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="72" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Lost of follow-up before end of study</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8300705198685017" CI_START="0.08860513027215278" EFFECT_SIZE="0.40268304759472423" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.26246782514008477" LOG_CI_START="-1.052541131562352" LOG_EFFECT_SIZE="-0.3950366532111337" ORDER="27" O_E="-1.5244755244755246" SE="0.7724427705663293" STUDY_ID="STD-Rimola-1995" TOTAL_1="72" TOTAL_2="71" VAR="1.6759743752750746" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2008-11-13 15:28:22 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Oral Cefixime versus IV ceftriaxone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.276782732001944" CI_START="0.24538995013666412" EFFECT_SIZE="1.2410718760912405" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7977370960036316" LOG_CI_START="-0.610143227630061" LOG_EFFECT_SIZE="0.09379693418678525" ORDER="14" O_E="0.3157894736842106" SE="0.8269958712224296" STUDY_ID="STD-Figueiredo-1996" TOTAL_1="20" TOTAL_2="18" VAR="1.4621546754510744" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:03:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.63976387065216" CI_START="0.17639445131594653" EFFECT_SIZE="1.8132707797299583" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.270440406391228" LOG_CI_START="-0.7535150802062781" LOG_EFFECT_SIZE="0.25846266309247495" ORDER="15" O_E="0.42105263157894735" SE="1.188881471568614" STUDY_ID="STD-Figueiredo-1996" TOTAL_1="20" TOTAL_2="18" VAR="0.707494197798907" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-07-23 15:57:34 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Any adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16" O_E="0.0" SE="0.0" STUDY_ID="STD-Figueiredo-1996" TOTAL_1="20" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2008-11-13 15:28:22 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Ofloxacin versus cefotaxime</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="64" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4854742856024603" CI_START="0.40793773361365915" EFFECT_SIZE="1.0069353241513064" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3954092743433639" LOG_CI_START="-0.38940612125250146" LOG_EFFECT_SIZE="0.0030015765454312815" ORDER="8" O_E="0.032520325203252654" SE="0.4610044482718744" STUDY_ID="STD-Navasa-1996" TOTAL_1="64" TOTAL_2="59" VAR="4.705326541470134" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:03:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="64" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.726379282774089" CI_START="0.3880340996527796" EFFECT_SIZE="1.028556333072348" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4355862729798433" LOG_CI_START="-0.41113010780704884" LOG_EFFECT_SIZE="0.01222808258639727" ORDER="9" O_E="0.11382113821138162" SE="0.497365393387902" STUDY_ID="STD-Navasa-1996" TOTAL_1="64" TOTAL_2="59" VAR="4.042489237367385" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-07-23 15:48:36 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="64" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Any adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.703762670756355" CI_START="0.12623049601897396" EFFECT_SIZE="0.9199017812370276" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8263186308302505" LOG_CI_START="-0.8988357112345755" LOG_EFFECT_SIZE="-0.03625854020216254" ORDER="10" O_E="-0.0813008130081303" SE="1.0133642001805978" STUDY_ID="STD-Navasa-1996" TOTAL_1="64" TOTAL_2="59" VAR="0.9737980146694712" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2008-11-13 15:28:20 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>IV + oral ciprofloxacin versus IV ciprofloxacin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.652129868693276" CI_START="0.37705544204466407" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.42359478665427375" LOG_CI_START="-0.42359478665427375" LOG_EFFECT_SIZE="0.0" ORDER="11" O_E="0.0" SE="0.4976433490174631" STUDY_ID="STD-Terg-1997" TOTAL_1="40" TOTAL_2="40" VAR="4.037974683544304" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-12 23:42:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.360706625535836" CI_START="0.3996764623827236" EFFECT_SIZE="1.1589630430692532" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.5264306021832669" LOG_CI_START="-0.3982914273173215" LOG_EFFECT_SIZE="0.06406958743297274" MODIFIED="2008-11-12 23:42:54 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.5" SE="0.5431862975765158" STUDY_ID="STD-Terg-1997" TOTAL_1="40" TOTAL_2="40" VAR="3.389240506329114" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2008-11-12 23:55:47 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Amoxicillin-clavulinic acid versus cefotaxime</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4962358741777804" CI_START="0.12371386169175212" EFFECT_SIZE="0.5557148366635714" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3972856202787589" LOG_CI_START="-0.9075816365150798" LOG_EFFECT_SIZE="-0.2551480081181605" ORDER="32" O_E="-1.0" SE="0.7664854858377946" STUDY_ID="STD-Ricart-2000" TOTAL_1="24" TOTAL_2="24" VAR="1.702127659574468" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:06:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.521111059345662" CI_START="0.14751449357952381" EFFECT_SIZE="0.7207044572892802" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5466797233662157" LOG_CI_START="-0.8311653073307153" LOG_EFFECT_SIZE="-0.1422427919822497" ORDER="33" O_E="-0.5" SE="0.8093529914742779" STUDY_ID="STD-Ricart-2000" TOTAL_1="24" TOTAL_2="24" VAR="1.526595744680851" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-12 23:54:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Any adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-12 23:54:57 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.0" STUDY_ID="STD-Ricart-2000" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.04" MODIFIED="2008-11-12 23:52:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="24" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Average number of days of hospitalisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.306601935235674" CI_START="-3.506601935235677" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" MEAN_1="18.4" MEAN_2="17.0" ORDER="36" SD_1="10.0" SD_2="7.1" SE="2.503414335129791" STUDY_ID="STD-Ricart-2000" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2008-11-13 15:29:05 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Ciprofloxacin versus cefotaxime</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.550051170622549" CI_START="0.20165457856788718" EFFECT_SIZE="1.1492814313343733" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8162446928211269" LOG_CI_START="-0.69539191288674" LOG_EFFECT_SIZE="0.06042638996719343" ORDER="48" O_E="0.17647058823529393" SE="0.887942824914679" STUDY_ID="STD-Tuncer-2003" TOTAL_1="16" TOTAL_2="18" VAR="1.2683233721296006" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:07:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.916912138745703" CI_START="0.193526531790086" EFFECT_SIZE="0.870647128024864" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5929438298869332" LOG_CI_START="-0.7132594863549452" LOG_EFFECT_SIZE="-0.06015782823400601" ORDER="49" O_E="-0.23529411764705888" SE="0.767270293771174" STUDY_ID="STD-Tuncer-2003" TOTAL_1="16" TOTAL_2="18" VAR="1.6986473733878582" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2008-11-13 15:30:00 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Ciprofloxacin versus ceftriaxone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1397450111403096" CI_START="0.13837616010541223" EFFECT_SIZE="0.6591402417935963" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.49689437904411426" LOG_CI_START="-0.8589387250995479" LOG_EFFECT_SIZE="-0.1810221730277169" ORDER="50" O_E="-0.657142857142857" SE="0.796423076856094" STUDY_ID="STD-Tuncer-2003" TOTAL_1="16" TOTAL_2="19" VAR="1.5765666266506602" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:08:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.1904507400575" CI_START="0.20874612809211374" EFFECT_SIZE="0.935275556693179" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.6222607397661443" LOG_CI_START="-0.6803815712399262" LOG_EFFECT_SIZE="-0.029060415736890884" ORDER="51" O_E="-0.11428571428571388" SE="0.7651785416684002" STUDY_ID="STD-Tuncer-2003" TOTAL_1="16" TOTAL_2="19" VAR="1.7079471788715486" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2008-11-13 15:30:31 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Cefotaxime versus ceftriaxone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-13 00:17:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="23.46776011172482" CI_START="0.3845707241112071" EFFECT_SIZE="3.004166023946433" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="1.3704716401934052" LOG_CI_START="-0.41502378000625145" LOG_EFFECT_SIZE="0.477723930093577" MODIFIED="2008-11-13 00:16:32 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="1.0" SE="1.0488088481701514" STUDY_ID="STD-Tuncer-2003" TOTAL_1="17" TOTAL_2="17" VAR="0.9090909090909092" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-13 00:19:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.526274878889206" CI_START="0.11124986103411963" EFFECT_SIZE="0.5301393488606666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.40248060349954845" LOG_CI_START="-0.9537005228382911" LOG_EFFECT_SIZE="-0.27560995966937135" MODIFIED="2008-11-13 00:19:02 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="-1.0" SE="0.7966275068156915" STUDY_ID="STD-Tuncer-2003" TOTAL_1="17" TOTAL_2="17" VAR="1.5757575757575757" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2008-11-13 15:30:31 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Moxifloxacin versus amoxicillin-clavulanic acid</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:08:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="352.82541670943306" CI_START="0.13847236894280432" EFFECT_SIZE="6.9897475830667375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.547559863135115" LOG_CI_START="-0.8586368779558022" LOG_EFFECT_SIZE="0.8444614925896565" ORDER="52" O_E="0.48571428571428577" SE="2.000816826662603" STUDY_ID="STD-Grange-2004" TOTAL_1="18" TOTAL_2="17" VAR="0.2497959183673469" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2008-11-13 15:30:51 +0100" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Amikacin versus cefotaxime</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.2814882921858874" CI_START="0.32411304657230555" EFFECT_SIZE="1.4268539895128152" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7980625546458051" LOG_CI_START="-0.4893034868933678" LOG_EFFECT_SIZE="0.1543795338762187" ORDER="44" O_E="0.6216216216216219" SE="0.7562051853647912" STUDY_ID="STD-Chen-2005" TOTAL_1="18" TOTAL_2="19" VAR="1.7487216946676407" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-13 00:26:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.225256909921754" CI_START="0.5708928166946373" EFFECT_SIZE="2.2949145740172763" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.964978469466085" LOG_CI_START="-0.24344542150462822" LOG_EFFECT_SIZE="0.3607665239807284" MODIFIED="2008-11-13 00:26:11 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="1.6486486486486482" SE="0.7098341753509304" STUDY_ID="STD-Chen-2005" TOTAL_1="18" TOTAL_2="19" VAR="1.9846603360116875" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:07:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3069755559122307" CI_START="0.012381464274258883" EFFECT_SIZE="0.12720955605950732" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.11626746513853471" LOG_CI_START="-1.9072279911296537" LOG_EFFECT_SIZE="-0.8954802629955594" ORDER="46" O_E="-1.4594594594594594" SE="1.1886112474759858" STUDY_ID="STD-Chen-2005" TOTAL_1="18" TOTAL_2="19" VAR="0.7078159240321402" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2008-11-13 15:30:52 +0100" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Ciprofloxacin versus ceftazidime</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-13 00:29:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="61" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4275040093673024" CI_START="0.20901666748998587" EFFECT_SIZE="0.5462345017174831" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.15457733670327975" LOG_CI_START="-0.6798190808252678" LOG_EFFECT_SIZE="-0.262620872060994" MODIFIED="2008-11-13 00:29:02 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="-2.517241379310345" SE="0.4901285859851487" STUDY_ID="STD-Angeli--2006" TOTAL_1="61" TOTAL_2="55" VAR="4.1627462131003465" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:06:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="61" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>No resolution of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.201546708555173" CI_START="0.4861808101616894" EFFECT_SIZE="1.2476099440673933" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.5053598422900611" LOG_CI_START="-0.3132021870092595" LOG_EFFECT_SIZE="0.09607882764040085" ORDER="40" O_E="0.9568965517241388" SE="0.48082738795781493" STUDY_ID="STD-Angeli--2006" TOTAL_1="61" TOTAL_2="55" VAR="4.325353487049578" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-11-11 00:06:42 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="61" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence of spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.477186519566185" CI_START="0.18060418471005493" EFFECT_SIZE="1.7766409379477368" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2424715211261177" LOG_CI_START="-0.7432721910356361" LOG_EFFECT_SIZE="0.24959966504524086" ORDER="41" O_E="0.4224137931034482" SE="1.166435686113719" STUDY_ID="STD-Angeli--2006" TOTAL_1="61" TOTAL_2="55" VAR="0.7349848782505299" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-015.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2008-07-23 16:07:16 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="61" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Any adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.477186519566185" CI_START="0.18060418471005493" EFFECT_SIZE="1.7766409379477368" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2424715211261177" LOG_CI_START="-0.7432721910356361" LOG_EFFECT_SIZE="0.24959966504524086" ORDER="42" O_E="0.4224137931034482" SE="1.166435686113719" STUDY_ID="STD-Angeli--2006" TOTAL_1="61" TOTAL_2="55" VAR="0.7349848782505299" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAAEACAMAAACQ12/OAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-11-14 01:16:42 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWMAAAJwCAIAAADTCpceAAAgTUlEQVR42u3dvW4lxdrF8S2REDiY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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-24 15:43:43 +0200" MODIFIED_BY="dimitrinka nikolova">
<APPENDIX ID="APP-01" MODIFIED="2008-10-24 15:43:43 +0200" MODIFIED_BY="dimitrinka nikolova" NO="1">
<TITLE MODIFIED="2008-10-24 15:43:31 +0200" MODIFIED_BY="dimitrinka nikolova">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-24 15:43:43 +0200" MODIFIED_BY="dimitrinka nikolova">
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time span</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>July 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(antibiotic* OR antibacteri*) AND periton* AND cirrho*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 3, 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor Anti-Bacterial Agents explode all trees in MeSH products<BR/>#2 antibiotic* in All Fields in all products<BR/>#3 antibacteri* NEAR agent in All Fields in all products<BR/>#4 (#1 OR #2 OR #3)<BR/>#5 MeSH descriptor Peritoneal Diseases explode all trees in MeSH products<BR/>#6 periton* in All Fields in all products<BR/>#7 (#5 OR #6)<BR/>#8 MeSH descriptor Liver Cirrhosis explode all trees in MeSH products<BR/>#9 cirrho* in All Fields in all products<BR/>#10 (#8 OR #9)<BR/>#11 (#4 AND #7 AND #10)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (WinSPIRS 5.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1950 to July 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 explode "Anti-Bacterial-Agents"/ all subheadings<BR/>#2 antibiotic*<BR/>#3 antibacteri* agent<BR/>#4 #1 or #2 or #3<BR/>#5 explode "Peritoneal-Diseases"/ all subheadings<BR/>#6 periton*<BR/>#7 #5 or #6<BR/>#8 explode "Liver-Cirrhosis"/ all subheadings<BR/>#9 cirrho*<BR/>#10 #8 or #9<BR/>#11 #4 and #7 and #10<BR/>#12 random* or blind* or placebo* or meta-analysis<BR/>#13 #11 and #12<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (WinSPIRS 5.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1980 to July 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 explode "antibiotic-agent"/ all subheadings<BR/>#2 antibiotic*<BR/>#3 antibacteri* agent<BR/>#4 #1 or #2 or #3<BR/>#5 explode "peritoneal-disease"/ all subheadings<BR/>#6 periton*<BR/>#7 #5 or #6<BR/>#8 explode "liver-cirrhosis"/ all subheadings<BR/>#9 cirrho*<BR/>#10 #8 or #9<BR/>#11 #4 and #7 and #10<BR/>#12 random* or blind* or placebo* or meta-analysis<BR/>#13 #11 and #12<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index EXPANDED<BR/>(http://portal.isiknowledge.com/portal.cgi?DestApp=WOS&amp;Func=Frame)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1945 to July 2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 TS=(antibiotic* OR antibacteri* agent)<BR/>#2 TS=(periton*)<BR/>#3 TS=(cirrho*)<BR/>#4 #3 AND #2 AND #1<BR/>#5 TS=(random* or blind* or placebo* or meta-analysis)<BR/>#6 #5 AND #4<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>